AU1359101A - Dna-vaccines based on constructs derived from the genomes of human and animal pathogens - Google Patents
Dna-vaccines based on constructs derived from the genomes of human and animal pathogens Download PDFInfo
- Publication number
- AU1359101A AU1359101A AU13591/01A AU1359101A AU1359101A AU 1359101 A AU1359101 A AU 1359101A AU 13591/01 A AU13591/01 A AU 13591/01A AU 1359101 A AU1359101 A AU 1359101A AU 1359101 A AU1359101 A AU 1359101A
- Authority
- AU
- Australia
- Prior art keywords
- genomic
- use according
- construct
- fragments
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960005486 vaccine Drugs 0.000 title claims description 36
- 244000037640 animal pathogen Species 0.000 title description 3
- 244000052637 human pathogen Species 0.000 title description 3
- 239000002245 particle Substances 0.000 claims description 129
- 239000012634 fragment Substances 0.000 claims description 127
- 108020004414 DNA Proteins 0.000 claims description 113
- 238000000034 method Methods 0.000 claims description 90
- 239000000203 mixture Substances 0.000 claims description 76
- 239000000427 antigen Substances 0.000 claims description 74
- 108091007433 antigens Proteins 0.000 claims description 70
- 102000036639 antigens Human genes 0.000 claims description 70
- 230000028993 immune response Effects 0.000 claims description 57
- 239000013612 plasmid Substances 0.000 claims description 54
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims description 52
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 51
- 244000052769 pathogen Species 0.000 claims description 42
- 150000007523 nucleic acids Chemical class 0.000 claims description 41
- 102000039446 nucleic acids Human genes 0.000 claims description 39
- 108020004707 nucleic acids Proteins 0.000 claims description 39
- 241000700605 Viruses Species 0.000 claims description 37
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 37
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 36
- 229910052737 gold Inorganic materials 0.000 claims description 31
- 239000010931 gold Substances 0.000 claims description 31
- 229920001184 polypeptide Polymers 0.000 claims description 30
- 108091026890 Coding region Proteins 0.000 claims description 27
- 230000000890 antigenic effect Effects 0.000 claims description 26
- 230000001404 mediated effect Effects 0.000 claims description 18
- 230000002068 genetic effect Effects 0.000 claims description 15
- 241000894006 Bacteria Species 0.000 claims description 14
- 230000001717 pathogenic effect Effects 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 11
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 230000037317 transdermal delivery Effects 0.000 claims description 9
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 238000012163 sequencing technique Methods 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 description 43
- 239000002671 adjuvant Substances 0.000 description 41
- 210000004027 cell Anatomy 0.000 description 41
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 37
- 102000040430 polynucleotide Human genes 0.000 description 35
- 239000002157 polynucleotide Substances 0.000 description 35
- 108091033319 polynucleotide Proteins 0.000 description 35
- 239000013598 vector Substances 0.000 description 34
- 102000004169 proteins and genes Human genes 0.000 description 29
- 241000699670 Mus sp. Species 0.000 description 17
- 208000015181 infectious disease Diseases 0.000 description 16
- 230000003053 immunization Effects 0.000 description 14
- 238000002649 immunization Methods 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- 230000004044 response Effects 0.000 description 14
- 241000700584 Simplexvirus Species 0.000 description 13
- 150000001413 amino acids Chemical class 0.000 description 13
- 230000003612 virological effect Effects 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 239000002773 nucleotide Substances 0.000 description 12
- 210000004989 spleen cell Anatomy 0.000 description 12
- 125000003729 nucleotide group Chemical group 0.000 description 11
- 239000000546 pharmaceutical excipient Substances 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 239000003981 vehicle Substances 0.000 description 11
- 239000000969 carrier Substances 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 210000003491 skin Anatomy 0.000 description 10
- 230000001105 regulatory effect Effects 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 238000013518 transcription Methods 0.000 description 9
- 230000035897 transcription Effects 0.000 description 9
- 108090000288 Glycoproteins Proteins 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 210000004379 membrane Anatomy 0.000 description 8
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 8
- 238000013519 translation Methods 0.000 description 8
- 230000014616 translation Effects 0.000 description 8
- 102000003886 Glycoproteins Human genes 0.000 description 7
- 238000010367 cloning Methods 0.000 description 7
- 238000004806 packaging method and process Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 7
- 229910052721 tungsten Inorganic materials 0.000 description 7
- 239000010937 tungsten Substances 0.000 description 7
- 241000701161 unidentified adenovirus Species 0.000 description 7
- 239000013603 viral vector Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 6
- 241000725303 Human immunodeficiency virus Species 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- 238000001415 gene therapy Methods 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 108010041986 DNA Vaccines Proteins 0.000 description 5
- 229940021995 DNA vaccine Drugs 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 241000282898 Sus scrofa Species 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 229910001873 dinitrogen Inorganic materials 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- -1 for example Substances 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 244000045947 parasite Species 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- 210000003501 vero cell Anatomy 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 108010049048 Cholera Toxin Proteins 0.000 description 4
- 102000009016 Cholera Toxin Human genes 0.000 description 4
- 241000701022 Cytomegalovirus Species 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000002238 attenuated effect Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000008030 elimination Effects 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000011859 microparticle Substances 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 230000001177 retroviral effect Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 229940063673 spermidine Drugs 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 229940031626 subunit vaccine Drugs 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 239000013607 AAV vector Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 231100000699 Bacterial toxin Toxicity 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108010053187 Diphtheria Toxin Proteins 0.000 description 3
- 102000016607 Diphtheria Toxin Human genes 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 241000711549 Hepacivirus C Species 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229920006355 Tefzel Polymers 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000000688 bacterial toxin Substances 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000013601 cosmid vector Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 208000029570 hepatitis D virus infection Diseases 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000008177 pharmaceutical agent Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000013600 plasmid vector Substances 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical class NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 241001529453 unidentified herpesvirus Species 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- 238000003260 vortexing Methods 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 208000004881 Amebiasis Diseases 0.000 description 2
- 206010001980 Amoebiasis Diseases 0.000 description 2
- 241000588832 Bordetella pertussis Species 0.000 description 2
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 108010039939 Cell Wall Skeleton Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 2
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 241000991587 Enterovirus C Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241000531123 GB virus C Species 0.000 description 2
- 206010048461 Genital infection Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 241000724675 Hepatitis E virus Species 0.000 description 2
- 241000709721 Hepatovirus A Species 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 101150027427 ICP4 gene Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102100034349 Integrase Human genes 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 241000712079 Measles morbillivirus Species 0.000 description 2
- 241000711386 Mumps virus Species 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 2
- 108010081690 Pertussis Toxin Proteins 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 108010001267 Protein Subunits Proteins 0.000 description 2
- 102000002067 Protein Subunits Human genes 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 241000725643 Respiratory syncytial virus Species 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 241000702670 Rotavirus Species 0.000 description 2
- 241000710799 Rubella virus Species 0.000 description 2
- 241000713311 Simian immunodeficiency virus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 206010044608 Trichiniasis Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 241000607479 Yersinia pestis Species 0.000 description 2
- 150000001242 acetic acid derivatives Chemical class 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 210000004520 cell wall skeleton Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000002716 delivery method Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 229940079920 digestives acid preparations Drugs 0.000 description 2
- 231100000676 disease causative agent Toxicity 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 108091006104 gene-regulatory proteins Proteins 0.000 description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000021633 leukocyte mediated immunity Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 150000002690 malonic acid derivatives Chemical class 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000006179 pH buffering agent Substances 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 239000000816 peptidomimetic Substances 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 235000011008 sodium phosphates Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000012798 spherical particle Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000013271 transdermal drug delivery Methods 0.000 description 2
- XETCRXVKJHBPMK-MJSODCSWSA-N trehalose 6,6'-dimycolate Chemical compound C([C@@H]1[C@H]([C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C(CCCCCCCCCCC3C(C3)CCCCCCCCCCCCCCCCCC)C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)O2)O)O1)O)OC(=O)C(C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)CCCCCCCCCCC1CC1CCCCCCCCCCCCCCCCCC XETCRXVKJHBPMK-MJSODCSWSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 208000003982 trichinellosis Diseases 0.000 description 2
- 201000007588 trichinosis Diseases 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 229960004854 viral vaccine Drugs 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- YHQZWWDVLJPRIF-JLHRHDQISA-N (4R)-4-[[(2S,3R)-2-[acetyl-[(3R,4R,5S,6R)-3-amino-4-[(1R)-1-carboxyethoxy]-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]amino]-3-hydroxybutanoyl]amino]-5-amino-5-oxopentanoic acid Chemical compound C(C)(=O)N([C@@H]([C@H](O)C)C(=O)N[C@H](CCC(=O)O)C(N)=O)C1[C@H](N)[C@@H](O[C@@H](C(=O)O)C)[C@H](O)[C@H](O1)CO YHQZWWDVLJPRIF-JLHRHDQISA-N 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- RSMRWWHFJMENJH-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;methyl sulfate Chemical compound COS([O-])(=O)=O.CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC RSMRWWHFJMENJH-LQDDAWAPSA-M 0.000 description 1
- OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 241000606750 Actinobacillus Species 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241001465677 Ancylostomatoidea Species 0.000 description 1
- 241000712892 Arenaviridae Species 0.000 description 1
- 201000002909 Aspergillosis Diseases 0.000 description 1
- 208000036641 Aspergillus infections Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000702628 Birnaviridae Species 0.000 description 1
- 241000588780 Bordetella parapertussis Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 241000714198 Caliciviridae Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 240000001817 Cereus hexagonus Species 0.000 description 1
- 102000001327 Chemokine CCL5 Human genes 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 241000223935 Cryptosporidium Species 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 102000000541 Defensins Human genes 0.000 description 1
- 108010002069 Defensins Proteins 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 201000006353 Filariasis Diseases 0.000 description 1
- 241000711950 Filoviridae Species 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 101710177291 Gag polyprotein Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 241000224466 Giardia Species 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 206010018693 Granuloma inguinale Diseases 0.000 description 1
- 241000186568 Hathewaya limosa Species 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000005331 Hepatitis D Diseases 0.000 description 1
- 208000001688 Herpes Genitalis Diseases 0.000 description 1
- 208000004898 Herpes Labialis Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 1
- 206010019973 Herpes virus infection Diseases 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 description 1
- 241000598171 Human adenovirus sp. Species 0.000 description 1
- 101001042049 Human herpesvirus 1 (strain 17) Transcriptional regulator ICP22 Proteins 0.000 description 1
- 101000999690 Human herpesvirus 2 (strain HG52) E3 ubiquitin ligase ICP22 Proteins 0.000 description 1
- 241000701027 Human herpesvirus 6 Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 125000000415 L-cysteinyl group Chemical group O=C([*])[C@@](N([H])[H])([H])C([H])([H])S[H] 0.000 description 1
- 241000589242 Legionella pneumophila Species 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 241000193386 Lysinibacillus sphaericus Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 101710151803 Mitochondrial intermediate peptidase 2 Proteins 0.000 description 1
- 241000588655 Moraxella catarrhalis Species 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 108700020354 N-acetylmuramyl-threonyl-isoglutamine Proteins 0.000 description 1
- 101000783356 Naja sputatrix Cytotoxin Proteins 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- GSBKRFGXEJLVMI-UHFFFAOYSA-N Nervonyl carnitine Chemical compound CCC[N+](C)(C)C GSBKRFGXEJLVMI-UHFFFAOYSA-N 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 241000243985 Onchocerca volvulus Species 0.000 description 1
- 206010067152 Oral herpes Diseases 0.000 description 1
- 206010048685 Oral infection Diseases 0.000 description 1
- 241000712464 Orthomyxoviridae Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- 241000606856 Pasteurella multocida Species 0.000 description 1
- 241000150350 Peribunyaviridae Species 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 241000233872 Pneumocystis carinii Species 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 241000702247 Reoviridae Species 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010039438 Salmonella Infections Diseases 0.000 description 1
- 241000242678 Schistosoma Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 206010040550 Shigella infections Diseases 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108010088897 Staphylococcus aureus epidermal cell differentiation inhibitor Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000122938 Strongylus vulgaris Species 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000008051 TBE buffer Substances 0.000 description 1
- 241000244155 Taenia Species 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 101710192266 Tegument protein VP22 Proteins 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 241000710924 Togaviridae Species 0.000 description 1
- 241000223996 Toxoplasma Species 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 241000242541 Trematoda Species 0.000 description 1
- 241000589886 Treponema Species 0.000 description 1
- 208000005448 Trichomonas Infections Diseases 0.000 description 1
- 206010044620 Trichomoniasis Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 201000007691 actinomycosis Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000002340 cardiotoxin Substances 0.000 description 1
- 231100000677 cardiotoxin Toxicity 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 208000017580 chronic wasting disease Diseases 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229920001940 conductive polymer Polymers 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 239000007771 core particle Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 210000000624 ear auricle Anatomy 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 238000005868 electrolysis reaction Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- QHSJIZLJUFMIFP-UHFFFAOYSA-N ethene;1,1,2,2-tetrafluoroethene Chemical compound C=C.FC(F)=C(F)F QHSJIZLJUFMIFP-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 201000004946 genital herpes Diseases 0.000 description 1
- 201000006592 giardiasis Diseases 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- ZWCXYZRRTRDGQE-SORVKSEFSA-N gramicidina Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 ZWCXYZRRTRDGQE-SORVKSEFSA-N 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000009616 inductively coupled plasma Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 201000006747 infectious mononucleosis Diseases 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000002743 insertional mutagenesis Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical group [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 206010023497 kuru Diseases 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 229940115932 legionella pneumophila Drugs 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 101710130522 mRNA export factor Proteins 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- JMUHBNWAORSSBD-WKYWBUFDSA-N mifamurtide Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O JMUHBNWAORSSBD-WKYWBUFDSA-N 0.000 description 1
- 229960005225 mifamurtide Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 1
- GKTNLYAAZKKMTQ-UHFFFAOYSA-N n-[bis(dimethylamino)phosphinimyl]-n-methylmethanamine Chemical compound CN(C)P(=N)(N(C)C)N(C)C GKTNLYAAZKKMTQ-UHFFFAOYSA-N 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 208000002042 onchocerciasis Diseases 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- UNEIHNMKASENIG-UHFFFAOYSA-N para-chlorophenylpiperazine Chemical compound C1=CC(Cl)=CC=C1N1CCNCC1 UNEIHNMKASENIG-UHFFFAOYSA-N 0.000 description 1
- 229940051027 pasteurella multocida Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 201000006509 pleuropneumonia Diseases 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 108010055896 polyornithine Proteins 0.000 description 1
- 229920002714 polyornithine Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 206010039447 salmonellosis Diseases 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 201000004409 schistosomiasis Diseases 0.000 description 1
- 208000008864 scrapie Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 208000037956 transmissible mink encephalopathy Diseases 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000007501 viral attachment Effects 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229910000859 α-Fe Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
WO 01/32221 PCT/USOO/30282 DNA-VACCINES BASED ON CONSTRUCTS DERIVED FROM THE GENOMES OF HUMAN AND ANIMAL PATHOGENS Technical Field 5 The present invention relates generally to vaccine compositions and methods of use thereof More particularly, the invention pertains to eliciting an immune response in a subject by administering one or more large genomic DNA fragments to the subject. 10 Background Vaccines which induce a cell-mediated immune response are emerging as important strategies in combating parasites, autoimmune disorders, allergic diseases and cancers. Conventional vaccination strategies generally involve administration of either "live" or "dead" vaccines. Ertl et al. (1996) J Immunol. 15 156:3579-3582. The so-called live vaccines include attenuated microbes and recombinant molecules based on a living vector. The dead vaccines include those based on killed whole pathogens, and subunit vaccines, e.g., soluble pathogen subunits or protein subunits. Live vaccines are generally successful in providing an effective immune response in immunized subjects; however, such vaccines 20 can be dangerous in immunocompromised or pregnant subjects, can revert to pathogenic organisms, or can be contaminated with other pathogens. Hassett et al. (1996) Trends in Microbiol. 8:307-312. Dead vaccines avoid the safety problems associated with live vaccines; however such vaccines often fail to provide an appropriate and/or effective immune response in immunized subjects. 25 More recently, direct injection of plasmid DNA by intramuscular (Wolff et al. (1990) Science 247:1465:1468) or intradermal injection with a needle and syringe (Raz et al. (1994) PNAS USA 91:9519-9523) has been described. Another approach referred to as ballistic or particle-mediated DNA delivery WO 01/32221 PCT/USOO/30282 -2 employs a needless particle delivery device to administer DNA-coated microscopic gold beads directly into the cells of the epidermis. (Yang et al. (1990) PNAS USA 87:9568-9572). Thus, a number of delivery techniques can be used to deliver nucleic acids for immunizations, including particle-mediated 5 techniques which deliver nucleic acid-coated microparticles into target tissue (see, e.g., co-owned U.S. Patent No. 5,865,796, issued February 2, 1999). Particle-mediated nucleic acid immunization techniques have been shown to elicit both humoral and cytotoxic T lymphocyte immune responses following epidermal delivery of nanogram quantities of DNA. Pertmer et al. (1995) 10 Vaccine 13:1427-1430. Such particle-mediated delivery techniques have been compared to other types of nucleic acid inoculation, and found markedly superior. Fynan et al. (1995) Int. J. Immunopharmacology 17:79-83, Fynan et al. (1993) Proc. Natl. Acad. Sci. USA 90:11478-11482, and Raz et al. (1994) Proc. Nati. Acad. Sci. USA 91:9519-9523. 15 A novel transdermal drug delivery system that entails the use of a needleless syringe to deliver solid drug-containing particles in controlled doses into and through intact skin has also been described. In particular, commonly owned U.S. Patent No. 5,630,796 to Bellhouse et al., describes a particle delivery device (e.g., a needleless syringe) that delivers pharmaceutical particles entrained 20 in a supersonic gas flow. The particle delivery device is used for transdermal delivery of powdered drug compounds and compositions, for delivery of genetic material into living cells (e.g., gene therapy) and for the delivery of biopharmaceuticals to skin, muscle, blood or lymph. The device can also be used in conjunction with surgery to deliver drugs and biologics to organ surfaces, solid 25 tumors and/or to surgical cavities (e.g., tumor beds or cavities after tumor resection). Pharmaceutical agents that can be suitably prepared in a substantially solid, particulate form can be safely and easily delivered using such a device. One particular particle delivery device generally comprises an elongate tubular nozzle having a rupturable membrane initially closing the passage WO 01/32221 PCT/USOO/30282 -3 through the nozzle and arranged substantially adjacent to the upstream end of the nozzle. Particles of a therapeutic agent to be delivered are disposed adjacent to the rupturable membrane and are delivered using an energizing means which applies a gaseous pressure to the upstream side of the membrane sufficient to 5 burst the membrane and produce a supersonic gas flow (containing the pharmaceutical particles) through the nozzle for delivery from the downstream end thereof. The particles can thus be delivered from the needleless syringe at delivery velocities of between Mach 1 and Mach 8 which are readily obtainable upon the bursting of the rupturable membrane. 10 Another particle delivery device configuration generally includes the same elements as described above, except that instead of having the pharmaceutical particles entrained within a supersonic gas flow, the downstream end of the nozzle is provided with a bistable diaphragm which is moveable between a resting "inverted" position (in which the diaphragm presents a 15 concavity on the downstream face to contain the pharmaceutical particles) and an active "everted" position (in which the diaphragm is outwardly convex on the downstream face as a result of a supersonic shockwave having been applied to the upstream face of the diaphragm). In this manner, the pharmaceutical particles contained within the concavity of the diaphragm are expelled at a high initial 20 velocity from the device for transdermal delivery thereof to a targeted skin or mucosal surface. Transdermal delivery using the above-described device configurations is generally carried out with particles having an approximate size that generally ranges between 0.1 and 250 gm. Particles larger than about 250 pm can also be 25 delivered from the device, with the upper limitation being the point at which the size of the particles would cause untoward damage to the skin cells. The actual distance which the delivered particles will penetrate depends upon particle size (e.g., the nominal particle diameter assuming a roughly spherical particle geometry), particle density, the initial velocity at which the particle impacts the WO 01/32221 PCTIUSOO/30282 -4 skin surface, and the density and kinematic viscosity of the skin. Target particle densities for use in needleless particle injection generally range between about 0.1 and 25 g/cm 3 , and injection velocities generally range between about 150 and 3,000 m/sec. 5 The level of effective protection achieved with DNA-vaccines is similar to that elicited by traditional protein subunit vaccines and killed or attenuated viral vaccines; but is traditionally less than that observed in convalescent animals following recovery from a natural infection. Manickan et al. (1997) Critical Review Immunol. 17:139-154. Herpes infections are extremely prevalent and are 10 caused by two viruses, herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2). HSV-1 is usually acquired in childhood and is the predominant cause of oral infections. HSV-2 infections are usually associated with sexually transmitted genital infections. However, up to 25% of genital herpes is caused by HSV-1. Natural infection appears to impart cross-protection 15 between the two HSV strains, in that, individuals infected with one strain (e.g., HSV- 1) have a low incidence of infection with the other strain (i.e., HSV-2) despite exposure. Mertz et al. (1992) Ann. Intern. Med. 116:197-202. The reasons for these observations have not been fully elucidated. Although near complete protection against infection with herpes simplex virus (HSV) can be 20 achieved in mice and/or guinea pigs by vaccination with killed or modified virus, the degree of protection in convalescent animals sets the target for improvement of vaccine performance. HSV is a double-stranded DNA virus having a genome of about 150-160 kbp. HSV-1 and HSV-2 genomes are colinear and share greater than 50% 25 homology over the entire genome. For some genes, the amino acid identity between the two virus types is as much as 80 to 90%. As a result of this similarity, many HSV-specific antibodies are cross-reactive for both virus types. The viral genome is packaged within an icosahedral nucleocapsid which is enveloped in a membrane. The membrane (or envelope) includes at least 10 WO 01/32221 PCTIUSOO/30282 -5 virus-encoded glycoproteins, the most abundant of which are gB, gC, gD, and gE. The viral glycoproteins are involved in the processes of virus attachment to cellular receptors and in fusion of the viral and host cell membranes to permit virus entry into the cell. The glycoproteins are located on the surface of the 5 virion. Consequently, they are targets of neutralizing antibody and antibody dependent cell cytotoxicity (ADCC). Within a virus type, there is a limited (1 to 2%) strain-to-strain sequence variability of the glycoprotein genes. The viral genome also encodes over 70 other proteins, including virion proteins, such as VP16 and VP22 which are associated with the virion tegument, located between 10 the capsid and the envelope. In addition, a group of approximately five ICPs are encoded by the virus. (See, e.g., WO/9516779 regarding ICP4-containing vaccines). These early proteins are synthesized early in the viral replication cycle, in contrast to the envelope glycoproteins which are only made late in the life cycle of the virus. 15 For a review of the molecular structure and organization of HSV, see, for example, Roizman and Sears (1996) "Herpes simplex viruses and their replication" in Fields Virology, 3rd ed., Fields et al. eds., Lippincott-Raven Publishers, Philadelphia, PA. One approach to HSV vaccine development has been the use of isolated 20 glycoproteins which have been shown to be both protective and therapeutic. See, e.g., Burke et al., Virology (1991) 18:793-797; Burke et al., Rev. Infect. Dis. (1991) 13(Suppl 11):S906-S911; Straus et al., Lancet (1994) 343:1460-1463; Ho et al., J Virol. (1989) 63:2951-2958; Stanberry et al., J. Infect. Dis. (1988) 157:156-163; and Stanberry et al., (1987) J. Infect. Dis. 155:914-920; Stanberry, 25 L.R. "Subunit Viral Vaccines: prophylactic and therapeutic use." In: Aurelian L (ed.) Herpesviruses, the Immune Systems and Aids. Kluwer, Boston, pp. 309 341. However, clinical trials have failed to demonstrate significant protective immunity in humans vaccinated with a subunit vaccine consisting of the gB and gD glycoproteins.
WO 01/32221 PCT/USOO/30282 -6 One method of identifying sequences encoding immunogenic epitopes involves the use of expression libraries, and is known as expression library immunization (ELI). International Publication WO 96/31613 reports that introducing cloned expression libraries from cDNA or fragmented genomic DNA 5 into a subject induces an immune response which can be quantified to select libraries including sequences with immunogenic epitopes. Selected pools are then identified and further characterized. The genomic fragments used are relatively small, between about 10 and 100 base pairs in length. Moreover, in the ELI method, genomic fragments are spliced into a vector having an exogenous 10 (e.g., heterologous) promoter. The genomic clones of ELI remain unidentified sequences and, accordingly, any antigenic sequences must be extensively purified and characterized before a specific vaccine can be developed. Despite these reports, there remains a need for methods of eliciting an immune response that more closely mimics an animal's natural response to 15 antigens. The present invention provides a solution to this and other problems. Summary of the Invention The present invention provides methods and compositions for eliciting immune responses in a subject. In one aspect, the invention provides a method 20 for eliciting an immune response in a vertebrate subject comprising administering constructs carrying genomic DNA fragments obtained or derived from one or more pathogens. Once the genomic DNA fragments have been administered to the subject, antigen encoded by coding sequences present in the genomic DNA fragments is expressed at an amount sufficient to elicit an immune response. The 25 genomic fragments are preferably greater than 5 kilobases (kb) in size. In certain methods, the construct is a plasmid carrying genomic DNA fragments between about 5 kb and 25 kb size. In yet other methods the construct is a cosmid carrying genomic DNA fragments between about 25 kb and about 50 kb in size. In certain methods, expression of coding sequences (i.e, antigen coding WO 01/32221 PCT/USOO/30282 -7 sequences) contained within the genomic DNA fragments is not driven by a heterologous promoter. The pathogens may be, for example, one or more types of bacteria or one or more types of viruses (e.g., a herpes simplex virus or "HSV"). The constructs (e.g,. plasmids or cosmids) may be administered, for 5 example, by transdermal administration. The invention thus also provides for the use of a genetic construct carrying a genomic DNA fragment at least 5 kb in size from a pathogen in the manufacture of a medicament for eliciting an immune response in a vertebrate subject by administering the said construct to the subject, whereby antigen 10 encoded by a sequence contained in said genomic DNA fragment is expressed in an amount sufficient to elicit an immune response. In another aspect, the invention provides a method for eliciting an immune response in a vertebrate subject. The method includes the steps of: (a) providing a core carrier coated with constructs carrying genomic DNA fragments 15 obtained or derived from one or more pathogens, wherein the genomic DNA fragments contain an antigen coding sequence; and (b) administering the coated core carrier to the subject using a particle-mediated transdermal delivery technique, whereby antigen encoded by a coding sequence present in the genomic DNA fragments is expressed in the subject in an amount sufficient to elicit an 20 immune response. The genomic DNA fragments are greater than about 5 kilobases in size. In certain methods, the construct is a plasmid and carries genomic DNA fragments ranging from about 5 to about 25 kilobases in size. In other methods, the construct is a cosmid and carries genomic DNA fragments from about 25 to about 50 kilobases in size. In certain methods, expression of 25 coding sequences contained within the genomic DNA fragments of the construct (e.g., plasmid or cosmid) is not driven by a heterologous promoter. For any of the plasmid or cosmid constructs described herein, the core carrier typically has an average diameter of about 0.5 to about 5 prm and a density sufficient to allow transdermal delivery into the subject. The core carrier can be comprised of a WO 01/32221 PCT/USOO/30282 -8 metal, for example, gold. The pathogens can be, for example, one or more types of bacteria, one or more viruses, or can be derived from two or more different pathogens. Still further methods involve repeating step (b) to provide a prime and a booster administration. 5 The invention thus also provides for the use of a genetic construct carrying genomic DNA fragments at least 5 kb in size encoding antigens from one or more pathogens in the manufacture of a medicament for eliciting an immune response in a vertebrate subject, wherein the genetic construct is coated on a core carrier and the coated core carrier is administered to the subject using a 10 transdermal particle-mediated delivery technique, and further wherein antigen encoded by a coding sequence present in the genomic fragments is expressed in the subject in an amount sufficient to elicit an immune response. In yet another aspect of the invention, a method is provided for identifying a sequence encoding an antigenic polypeptide. The method entails 15 the steps of: (a) administering constructs carrying genomic DNA fragments obtained or derived from one or more pathogens, wherein the genomic DNA fragments contain or are suspected of containing a coding sequence for the antigenic polypeptide and, upon delivery to the subject, the antigenic polypeptide is expressed from the coding sequence in an amount sufficient to elicit an 20 immune response; and (b) identifying the sequence on the construct encoding the antigenic polypeptide. In one method, step (b) comprises administering one or more fragments of the constructs of step (a) and identifying which fragment encodes the antigenic polypeptide. In another method, step (b) comprises sequencing the construct. 25 The invention thus further provides for the use of a genetic construct carrying genomic DNA fragments at least 5 kb in size from one or more pathogens in the manufacture of a composition for identifying a sequence encoding an antigenic polypeptide by administering the said construct to a subject, wherein the genomic DNA fragments contain a coding sequence for said WO 01/32221 PCT/USOO/30282 -9 antigenic polypeptide and, upon delivery, the antigenic polypeptide is expressed in an amount sufficient to elicit an immune response; and identifying the sequence on the construct encoding the antigenic polypeptide. In a related aspect, the invention provides a vaccine composition 5 comprising one or more constructs carrying genomic DNA fragments obtained or derived from one or more pathogens, for example, a vaccine composition comprising one or more constructs (e.g., clone #68) carrying genomic DNA fragments from herpes simplex virus-2 (HSV-2). In certain embodiments, the construct is a plasmid carrying genomic DNA fragments ranging from about 5 kb 10 to 25 kb in size. In yet other embodiments the construct is a cosmid carrying genomic DNA fragments ranging from about 25 kb to about 50 kb in size. In any of the methods or compositions described herein, the genomic fragments can include the immediate early regions (e.g., ICP27, ICPO, ICP4, ICP22, etc.) of a virus such as HSV-2, for example the region spanning from approximately 15 nucleotide 114589 to 134980 of the HSV-2 genome, or an EcoRI fragment that spans nucleotides 110931 to 139697 of the HSV-2 genome. The sequence of the HSV-2 genome is available form published sources, for example the sequence deposited with GenBank under Accession Number NC_001798. In certain embodiments, expression of coding sequences contained within the genomic 20 DNA fragments of the construct (e.g., plasmid or cosmid) is not driven by a heterologous promoter. The vaccine compositions may also comprise one or more adjuvants. These and other embodiments of the present invention will readily occur to those of ordinary skill in the art in view of the disclosure herein. 25 Brief Description of the Drawings Figure 1 is a schematic representation of various HSV-2 cosmids used in the present invention. The numbers represent the designations for the cosmid WO 01/32221 PCT/USOO/30282 -10 clones that have been used to immunize animals. Each cosmid contains approximately 30,000-40,000 base pairs of DNA from HSV-2. Figure 2 depicts serum antibody levels in mice immunized with HSV-2 cosmids. 5 Figure 3 depicts antigen-specific spleen cell proliferation in animals immunized with either an HSV-2 gD plasmid or an HSV-2 cosmid. Modes for Carrying out the Invention Before describing the present invention in detail, it is to be understood 10 that this invention is not limited to particular antigens or to antigen-coding nucleotide sequences. It is also to be understood that different applications of the disclosed methods may be tailored to the specific needs in the art. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments of the invention only, and is not intended to be limiting. 15 All publications, patents and patent applications cited herein, whether supra or infra, are hereby incorporated by reference in their entirety. It must be noted that, as used in this specification and the appended claims, the singular forms "a", "an", and "the" include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to "an antigen" 20 includes a mixture of two or more such agents, reference to "a particle" includes reference to mixtures of two or more particles, reference to "a recipient cell" includes two or more such cells, and the like. Definitions 25 Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. The following terms are intended to be defined as indicated below.
WO 01/32221 PCT/USOO/30282 -11~ The term "vaccine composition" intends any pharmaceutical composition containing an antigen (e.g., polynucleotide encoding an antigen), which composition can be used to prevent or treat a disease or condition in a subject. The term thus encompasses both subunit vaccines, i.e., vaccine compositions 5 containing antigens which are separate and discrete from a whole organism with which the antigen is associated in nature, as well as compositions containing whole killed, attenuated or inactivated bacteria, viruses, parasites or other microbes. The term "transdermal" delivery intends intradermal (e.g., into the dermis 10 or epidermis), transdermal (e.g., "percutaneous") and transmucosal administration, i.e., delivery by passage of an agent into or through skin or mucosal tissue. See, e.g., Transdermal Drug Delivery: Developmental Issues and Research Initiatives, Hadgraft and Guy (eds.), Marcel Dekker, Inc., (1989); Controlled Drug Delivery: Fundamentals and Applications, Robinson and Lee 15 (eds.), Marcel Dekker Inc., (1987); and Transdermal Delivery ofDrugs, Vols. 1 3, Kydonieus and Berner (eds.), CRC Press, (1987). Thus, the term encompasses delivery from a particle delivery device (e.g., needleless syringe) as described in U.S. Patent No. 5,630,796, as well as particle-mediated delivery as described in U.S. Patent No. 5,865,796. 20 By "core carrier" is meant a carrier particle on which a nucleic acid (e.g., DNA) is coated in order to impart a defined particle size as well as a sufficiently high density to achieve the momentum required for cell membrane penetration, such that the DNA can be delivered using particle-mediated delivery techniques, for example those described in U.S. Patent No. 5,100,792. Core carriers typically 25 include materials such as tungsten, gold, platinum, ferrite, polystyrene and latex. See e.g., Particle Bombardment Technology for Gene Transfer, (1994) Yang, N. ed., Oxford University Press, New York, NY pages 10-11. By "particle delivery device," or "needleless syringe," is meant an instrument which delivers a particulate composition transdermally, without a WO 01/32221 PCTIUSOO/30282 -12 conventional needle that pierces the skin. Particle delivery devices for use with the present invention are discussed throughout this document. By "antigen" is meant a molecule which contains one or more epitopes that will stimulate a host's immune system to make a cellular antigen-specific 5 immune response, or a humoral antibody response. Thus, antigens include proteins, polypeptides, antigenic protein fragments, oligosaccharides, polysaccharides, and the like. Furthermore, the antigen can be derived from any known virus, bacterium, parasite, plants, protozoans, or fungus, and can be a whole organism. The term also includes tumor antigens. Similarly, an 10 oligonucleotide or polynucleotide which expresses an antigen, such as in DNA immunization applications, is also included in the definition of antigen. Synthetic antigens are also included, for example, polyepitopes, flanking epitopes, and other recombinant or synthetically derived antigens (Bergmann et al. (1993) Eur. J Immunol. 23:2777-2781; Bergmann et al. (1996) J. Immunol. 15 157:3242-3249; Suhrbier, A. (1997) Immunol. and Cell Biol. 75:402-408; Gardner et al. (1998) 12th World AIDS Conference, Geneva, Switzerland, June 28-July 3, 1998). By "suitable immune response" is meant that the methods of the invention can bring about in an immunized subject an immune response characterized by 20 the production of B and/or T lymphocytes specific for an antigen or antigens. The term "peptide" is used in it broadest sense to refer to a compound of two or more subunit amino acids, amino acid analogs, or other peptidomimetics. The subunits may be linked by peptide bonds or by other bonds, for example ester, ether, etc. As used herein, the term "amino acid" refers to either natural 25 and/or unnatural or synthetic amino acids, including glycine and both the D or L optical isomers, and amino acid analogs and peptidomimetics. A peptide of three or more amino acids is commonly called an oligopeptide if the peptide chain is short. If the peptide chain is long, the peptide is typically called a polypeptide or a protein.
WO 01/32221 PCT/USOO/30282 -13 The term "pathogen" is used in a broad sense to refer to the source of any molecule that elicits an immune response. Thus, pathogens include, but are not limited to, virulent or attenuated viruses, bacteria, fungi, protozoa, parasites, cancer cells and the like. Typically, the immune response is elicited by one or 5 more peptides produced by these pathogens. As described in detail below, genomic DNA encoding the antigenic peptides from these and other pathogens is used to generate an immune response that mimics the response to natural infection. It will also be apparent in view of the teachings herein, that the methods include the use of genomic DNA obtained from more than one 10 pathogen. The terms "nucleic acid molecule" and "polynucleotide" are used interchangeably to and refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof. Polynucleotides may have any three-dimensional structure, and may perform any 15 function, known or unknown. Non-limiting examples of polynucleotides include a gene, a gene fragment, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. 20 A polynucleotide is typically composed of a specific sequence of four nucleotide bases: adenine (A); cytosine (C); guanine (G); and thymine (T) (uracil (U) for thymine (T) when the polynucleotide is RNA). Thus, the term polynucleotide sequence is the linear representation of a polynucleotide molecule. This linear representation can be input into databases in a computer having a 25 central processing unit and used for bioinformatics applications such as functional genomics and homology searching. A "vector" or "construct" is any moiety capable of transferring gene sequences to target cells (e.g., viral vectors, non-viral vectors, particulate carriers, and liposomes). A "plasmid" vector is an extrachromosomal genetic element WO 01/32221 PCT/USOO/30282 -14 which is capable of self-replication in a host cell. A "cosmid" vector is a special type of plasmid vector that uses the cos sequences of bacteriophage lambda (X). The term "cos ends" or "cos sites" refers to the single stranded 12 base pair complementary extensions of X DNA. Cosmids can carry large inserts, for 5 example up to around 50 kb in size, while typical plasmids carry fragments under about 10 kb in size. Because of their capacity to carry large fragments, cosmids are useful for the construction of genomic libraries. Typically, "vector," "construct," "expression vector," and "gene transfer vector," mean any nucleic acid construct capable of directing the expression of a gene of interest and which 10 can transfer gene sequences to target cells. Thus, the term includes cloning and expression vehicles, as well as viral vectors. A "genomic library" is a collection of recombinant nucleic acid molecules which together represent the entire genome of an organism. A "coding sequence" or a sequence which "encodes" a selected 15 polypeptide, is a nucleic acid molecule which is transcribed (in the case of DNA) and translated (in the case of mRNA) into a polypeptide in vivo when placed under the control of appropriate regulatory sequences (or "control elements"). The boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxy) terminus. A 20 coding sequence can include, but is not limited to, cDNA from viral, procaryotic or eucaryotic mRNA, genomic DNA sequences from viral or procaryotic DNA, and even synthetic DNA sequences. A transcription termination sequence may be located 3' to the coding sequence. Transcription and translation of coding sequences are typically regulated by "control elements," including, but not 25 limited to, transcription promoters, transcription enhancer elements, Shine and Delagarno sequences, transcription termination signals, polyadenylation sequences (located 3' to the translation stop codon), sequences for optimization of initiation of translation (located 5' to the coding sequence), and translation termination sequences.
WO 01/32221 PCT/USOO/30282 -15 A "promoter" is a nucleotide sequence which directs transcription of a polypeptide-encoding polynucleotide. Promoters can include inducible promoters (where expression of a polynucleotide sequence operably linked to the promoter is induced by an analyte, cofactor, regulatory protein, etc.), repressible 5 promoters (where expression of a polynucleotide sequence operably linked to the promoter is repressed by an analyte, cofactor, regulatory protein, etc.), and constitutive promoters. It is intended that the term "promoter" or "control element" includes full-length promoter regions and functional (e.g., controls transcription or translation) segments of these regions. 10 An "isolated polynucleotide" molecule is a nucleic acid molecule separate and discrete from the whole organism with which the molecule is found in nature; or a nucleic acid molecule devoid, in whole or part, of sequences normally associated with it in nature; or a sequence, as it exists in nature, but having heterologous sequences (as defined below) in association therewith. A sequence 15 is "derived or obtained from" a molecule if it has the same or substantially the same basepair sequence as a region of the source molecule, its cDNA, complements thereof, or if it displays sequence identity as described below. "Operably linked" refers to an arrangement of elements wherein the components so described are configured so as to perform their usual function. 20 Thus, a given promoter that is operably linked to a coding sequence (e.g., encoding an antigen of interest) is capable of effecting the expression of the coding sequence when the proper enzymes are present. The promoter or other control elements need not be contiguous with the coding sequence, so long as they function to direct the expression thereof. For example, intervening 25 untranslated yet transcribed sequences can be present between the promoter sequence and the coding sequence and the promoter sequence can still be considered "operably linked" to the coding sequence. "Recombinant" as used herein to describe a nucleic acid molecule means a polynucleotide of genomic, cDNA, semisynthetic, or synthetic origin which, by WO 01/32221 PCT/USOO/30282 -16 virtue of its origin or manipulation: (1) is not associated with all or a portion of the polynucleotide with which it is associated in nature; and/or (2) is linked to a polynucleotide other than that to which it is linked in nature. The term "recombinant" as used with respect to a protein or polypeptide means a 5 polypeptide produced by expression of a recombinant polynucleotide. Techniques for determining nucleic acid and amino acid "sequence identity" also are known in the art. Typically, such techniques include determining the nucleotide sequence of the mRNA for a gene and/or determining the amino acid sequence encoded thereby, and comparing these sequences to a 10 second nucleotide or amino acid sequence. In general, "identity" refers to an exact nucleotide-to-nucleotide or amino acid-to-amino acid correspondence of two polynucleotides or polypeptide sequences, respectively. Two or more sequences (polynucleotide or amino acid) can be compared by determining their "percent identity." The percent identity of two sequences, whether nucleic acid 15 or amino acid sequences, is the number of exact matches between two aligned sequences divided by the length of the shorter sequences and multiplied by 100. An approximate alignment for nucleic acid sequences is provided by the local homology algorithm of Smith and Waterman, Advances in Applied Mathematics 2:482-489 (1981). This algorithm can be applied to amino acid sequences by 20 using the scoring matrix developed by Dayhoff, Atlas of Protein Sequences and Structure, M.O. Dayhoff ed., 5 supply. 3:353-358, National Biomedical Research Foundation, Washington, D.C., USA, and normalized by Gribskov, Nucl. Acids Res. 14(6):6745-6763 (1986). An exemplary implementation of this algorithm to determine percent identity of a sequence is provided by the Genetics Computer 25 Group (Madison, WI) in the "BestFit" utility application. The default parameters for this method are described in the Wisconsin Sequence Analysis Package Program Manual, Version 8 (1995) (available from Genetics Computer Group, Madison, WI). A preferred method of establishing percent identity in the context of the present invention is to use the MPSRCH package of programs copyrighted WO 01/32221 PCT/USOO/30282 -17 by the University of Edinburgh, developed by John F. Collins and Shane S. Sturrok, and distributed by IntelliGenetics, Inc. (Mountain View, CA). From this suite of packages the Smith-Waterman algorithm can be employed where default parameters are used for the scoring table (for example, gap open penalty of 12, 5 gap extension penalty of one, and a gap of six). From the data generated the "Match" value reflects "sequence identity." Other suitable programs for calculating the percent identity or similarity between sequences are generally known in the art, for example, another alignment program is BLAST, used with default parameters. For example, BLASTN and BLASTP can be used using the 10 following default parameters: genetic code = standard; filter = none; strand = both; cutoff= 60; expect = 10; Matrix = BLOSUM62; Descriptions = 50 sequences; sort by = HIGH SCORE; Databases = non-redundant, GenBank + EMBL + DDBJ + PDB + GenBank CDS translations + Swiss protein + Spupdate + PIR. Details of these programs can be found at the following internet address: 15 http://www.ncbi.nlm.gov/cgi-bin/BLAST. Alternatively, homology can be determined by hybridization of polynucleotides under conditions which form stable duplexes between homologous regions, followed by digestion with single-stranded-specific nuclease(s), and size determination of the digested fragments. Two DNA, or two 20 polypeptide sequences are "substantially homologous" to each other when the sequences exhibit at least about 80%-85%, preferably at least about 90%, and most preferably at least about 95%-98% sequence identity over a defined length of the molecules, as determined using the methods above. As used herein, substantially homologous also refers to sequences showing complete identity to 25 the specified DNA or polypeptide sequence. DNA sequences that are substantially homologous can be identified in a Southern hybridization experiment under, for example, stringent conditions, as defined for that particular system. For example, stringent hybridization conditions can include 50% formamide, 5x Denhardt's Solution, 5x SSC, 0.1% SDS and 100 gg/ml denatured WO 01/32221 PCT/USOO/30282 -18 salmon sperm DNA and the washing conditions can include 2x SSC, 0.1% SDS at 37'C followed by 1x SSC, 0.1% SDS at 68'C. Defining appropriate hybridization conditions is within the skill of the art. See, e.g., Sambrook et al., supra; DNA Cloning, supra; Nucleic Acid Hybridization, supra. 5 As used herein the term "adjuvant" refers to any material that enhances the action of a drug, antigen, polynucleotide, vector or the like. It is intended, although not always explicitly stated, that molecules having similar biological activity as wild-type or purified peptide adjuvants (e.g., recombinantly produced or muteins thereof) and nucleic acid encoding these molecules are intended to be 10 used within the spirit and scope of the invention. As used herein, the term "treatment" includes any of following: the prevention of infection or reinfection; the reduction or elimination of symptoms; and the reduction or complete elimination of a pathogen. Treatment may be effected prophylactically (prior to infection) or therapeutically (following 15 infection). By "vertebrate subject" is meant any member of the subphylum cordata, particularly mammals, including, without limitation, humans and other primates. The term does not denote a particular age. Thus, both adult and newborn individuals are intended to be covered. 20 General Overview of the Invention Before describing the present invention in detail, it is to be understood that this invention is not limited to particular formulations or process parameters as such may, of course, vary. It is also to be understood that the terminology 25 used herein is for the purpose of describing particular embodiments of the invention only, and is not intended to be limiting. The present invention provides novel methods of eliciting an immune response in a subject. Briefly, vector libraries carrying large polynucleotide (e.g., DNA) fragments representing the genomes of one or more pathogens (e.g., cells, WO 01/32221 PCT/USOO/30282 -19 tissues, viruses, etc.) are generated. The vectors are typically in the form of plasmids or cosmids, depending upon the size of the genomic fragments. The libraries may contain overlapping or non-overlapping inserts. One or more selected clones of the genomic library are then administered to a subject in an 5 amount effective to elicit an immune response. In this way, a large number of antigens (and their corresponding epitopes) can be administered to the subject in a single immunization step. In addition, because the large genomic fragments carried by the constructs (e.g,. cosmids or plasmids) include their endogenous expression control elements, further molecular manipulations (for example 10 insertion of heterologous promoter sequences to drive expression from coding sequences present in the genomic fragments) are not required. However, heterologous control may be present in the constructs, for example when the genomic sequences are derived from prokaryotes such as bacteria. Further, because the endogenous control elements (e.g., cis and/or trans-acting regulatory 15 elements) drive antigen expression in the host subject and the immunogenic gene products are thus produced at levels similar to that of a natural infection, the overall immune response elicited by the constructs more closely mimics the response due to natural infection. In contrast, the use of heterologous promoters in previously described expression library immunization would result in non 20 selective expression of the pathogen's genes. The invention also includes an efficient method for identifying sequences encoding antigenic fragments. In particular, use of constructs having a known genetic composition allows for a method of identifying sequences that encode antigenic polypeptides. For example, a cosmid or plasmid clone that induces an 25 immune response in a subject is identified. The precise sequence(s) involved in the immune response can then be determined by methods known in the art, for example sequencing of the clone, or by further fragmenting of the cosmid or plasmid insert and testing these smaller fragments for their immunogenicity.
WO 01/32221 PCT/USOO/30282 -20 The polynucleotides of the present invention may be introduced into cells in vitro or in vivo, for example by conventional transfection techniques or by coating the polynucleotides onto particles and then administering the coated particles to the cells using particle-mediated transfection. Alternatively, the 5 polynucleotides may be provided in a particulate (e.g., powder) form, discussed more fully below and in the disclosure of International Publication Number WO 98/10750, which is incorporated by reference herein. Advantages of the present invention include, but are not limited to, (i) expanding the number of antigens used to elicit an immune response; (ii) 10 providing an array of antigens (e.g., epitopes) which more closely mimics that of a natural infection; (iii) achieving co-delivery of the antigens and their associated wild-type regulatory elements into the same cell to achieve coordinated expression of multiple antigens; (iv) eliciting an immune response similar to that elicited by natural infection; (v) eliciting an immune response that is more 15 protective than that elicited by natural infection, e.g., by elimination of an immunodominant antigen or elimination of genes that inhibit immune responses; (vi) identifying the most effective combination of antigens for subsequent production of plasmids for use in eliciting an immune response; and (vii) triggering the antigen processing and presentation pathways that are normally 20 involved in the clearance of intracellular infections. Antigens The methods described herein are useful in eliciting an immune response against a wide variety of cells, tissues and human or animal pathogens. These 25 pathogens contain one or more antigens. Non-limiting examples of sources for genomic DNA for cosmid or plasmid libraries include viruses, bacterial cells, fungal cells, and other pathogenic organisms. Suitable viral antigens include, but are not limited to, those obtained or derived from the hepatitis family of viruses, including hepatitis A virus (HAV), WO 01/32221 PCTIUSOO/30282 -21 hepatitis B virus (HBV), hepatitis C virus (HCV), the delta hepatitis virus (HDV), hepatitis E virus (HEV) and hepatitis G virus (HGV). See, e.g., International Publication Nos. WO 89/04669; WO 90/11089; and WO 90/14436. The HCV genome encodes several viral proteins, including El and E2. See, e.g., Houghton 5 et al. (1991) Hepatology 14:381-388. Genomic fragments containing sequences encoding these proteins, as well as antigenic fragments thereof, will find use in the present methods. Similarly, the coding sequence for the 6-antigen from HDV is known (see, e.g., U.S. Patent No. 5,378,814). In like manner, a wide variety of proteins from the herpesvirus family can 10 be used as antigens in the present invention, including proteins derived from herpes simplex virus (HSV) types 1 and 2, such as HSV-1 and HSV-2 glycoproteins gB, gD and gH; antigens from varicella zoster virus (VZV), Epstein-Barr virus (EBV) and cytomegalovirus (CMV) including CMV gB and gH; and antigens from other human herpesviruses such as HHV6 and HHV7. 15 (See, e.g. Chee et al. (1990) Cytomegaloviruses (J.K. McDougall, ed., Springer Verlag, pp. 125-169; McGeoch et al. (1988) J. Gen. Virol. 69:1531-1574; U.S. Patent No. 5,171,568; Baer et al. (1984) Nature 310:207-211; and Davison et al. (1986) J. Gen. Virol. 67:1759-1816.) Human immunodeficiency virus (HIV) antigens, such as gp120 molecules 20 for a multitude of HIV-1 and HIV-2 isolates, including members of the various genetic subtypes of HIV, are known and reported (see, e.g., Myers et al., Los Alamos Database, Los Alamos National Laboratory, Los Alamos, New Mexico (1992); and Modrow et al. (1987) J. Virol. 61:570-578) and antigen-containing genomic fragments derived or obtained from any of these isolates will find use in 25 the present invention. Furthermore, other immunogenic proteins derived or obtained from any of the various HIV isolates will find use herein, including fragments containing one or more of the various envelope proteins such as gp160 and gp4l, gag antigens such as p24gag and p55gag, as well as proteins derived from the pol, env, tat, vif, rev, nef, vpr, vpu and LTR regions of HIV.
WO 01/32221 PCT/USOO/30282 -22 Antigens derived or obtained from other viruses will also find use herein, such as without limitation, antigens from members of the families Picornaviridae (e.g., polioviruses, rhinoviruses, etc.); Caliciviridae; Togaviridae (e.g., rubella virus, dengue virus, etc.); Flaviviridae; Coronaviridae; Reoviridae (e.g., rotavirus, 5 etc.); Birnaviridae; Rhabodoviridae (e.g., rabies virus, etc.); Orthomyxoviridae (e.g., influenza virus types A, B and C, etc.); Filoviridae; Paramyxoviridae (e.g., mumps virus, measles virus, respiratory syncytial virus, parainfluenza virus, etc.); Bunyaviridae; Arenaviridae; Retroviradae (e.g., HTLV-I; HTLV-II; HIV-1 (also known as HTLV-III, LAV, ARV, hTLR, etc.)), including but not limited to 10 antigens from the isolates HIVIIIh, HIVSF 2 , HIVLAV, HIVLM, HIVM); HIV- CM235 HIV-l US 4 ; HIV-2, among others; simian immunodeficiency virus (SIV); Papillomavirus, the tick-bourne encephalitis viruses; and the like. See, e.g. Virology, 3rd Edition (W.K. Joklik ed. 1988); Fundamental Virology, 2nd Edition (B.N. Fields and D.M. Knipe, eds. 1991), for a description of these and 15 other viruses. In some contexts, it may be preferable that the selected viral antigens are obtained or derived from a viral pathogen that typically enters the body via a mucosal surface and is known to cause or is associated with human disease, such as, but not limited to, HIV (AIDS), influenza viruses (Flu), herpes simplex 20 viruses (genital infection, cold sores, STDs), rotaviruses (diarrhea), parainfluenza viruses (respiratory infections), poliovirus (poliomyelitis), respiratory syncytial virus (respiratory infections), measles and mumps viruses (measles, mumps), rubella virus (rubella), and rhinoviruses (common cold). Genomic fragments containing bacterial and parasitic antigens can be 25 obtained or derived from known causative agents responsible for diseases including, but not limited to, Diptheria, Pertussis, Tetanus, Tuberculosis, Bacterial or Fungal Pneumonia, Otitis Media, Gonnorhea, Cholera, Typhoid, Meningitis, Mononucleosis, Plague, Shigellosis or Salmonellosis, Legionaire's Disease, Lyme Disease, Leprosy, Malaria, Hookworm, Onchocerciasis, WO 01/32221 PCT/USOO/30282 -23 Schistosomiasis, Trypamasomialsis, Lesmaniasis, Giardia, Amoebiasis, Filariasis, Borelia, and Trichinosis. Still further antigens can be obtained or derived from unconventional viruses such as the causative agents of kuru, Creutzfeldt-Jakob disease (CJD), scrapie, transmissible mink encephalopathy, 5 and chronic wasting diseases, or from proteinaceous infectious particles such as prions that are associated with mad cow disease. Specific pathogens can include M. tuberculosis, Chlamydia, N. gonorrhoeae, Shigella, Salmonella, Vibrio Cholera, Treponema pallidua, Pseudomonas, Bordetella pertussis, Brucella, Franciscella tulorensis, 10 Helicobacter pylori, Leptospria interrogaus, Legionella pneumophila, Yersinia pestis, Streptococcus (types A and B), Pneumococcus, Meningococcus, Hemophilus influenza (type b), Toxoplasma gondic, Complylobacteriosis, Moraxella catarrhalis, Donovanosis, and Actinomycosis; fungal pathogens including Candidiasis and Aspergillosis; parasitic pathogens including Taenia, 15 Flukes, Roundworms, Amebiasis, Giardiasis, Cryptosporidium, Schistosoma, Pneumocystis carinii, Trichomoniasis and Trichinosis. Thus, the present invention can also be used to provide a suitable immune response against numerous veterinary diseases, such as Foot and Mouth diseases, Coronavirus, Pasteurella multocida, Helicobacter, Strongylus vulgaris, Actinobacillus 20 pleuropneumonia, Bovine viral diarrhea virus (BVDV), Klebsiella pneumoniae, E. coli, Bordetella pertussis, Bordetella parapertussis and brochiseptica. Adjuvants In some embodiments, the present invention may effectively be used with 25 any suitable adjuvant or combination of adjuvants. For example, suitable adjuvants include, without limitation, adjuvants formed from aluminum salts (alum), such as aluminum hydroxide, aluminum phosphate, aluminum sulfate, etc; oil-in-water and water-in-oil emulsion formulations, such as Complete Freunds Adjuvants (CFA) and Incomplete Freunds Adjuvant (IFA); adjuvants WO 01/32221 PCTUSOO/30282 -24 formed from bacterial cell wall components such as adjuvants including lipopolysaccharides (e.g., lipid A or monophosphoryl lipid A (MPL), Imoto et al. (1985) Tet. Lett. 26:1545-1548), trehalose dimycolate (TDM), and cell wall skeleton (CWS); heat shock protein or derivatives thereof; adjuvants derived 5 from ADP-ribosylating bacterial toxins, including diphtheria toxin (DT), pertussis toxin (PT), cholera toxin (CT), the E. coli heat-labile toxins (LT1 and LT2), Pseudomonas endotoxin A, Pseudomonas exotoxin S, B. cereus exoenzyme, B. sphaericus toxin, C. botulinum C2 and C3 toxins, C. limosum exoenzyme, as well as toxins from C. perfringens, C. spiriforma and C. difficile, 10 Staphylococcus aureus EDIN, and ADP-ribosylating bacterial toxin mutants such as CRM 1 97 , a non-toxic diphtheria toxin mutant (see, e.g., Bixler et al. (1989) Adv. Exp. Med. Biol. 251:175; and Constantino et al. (1992) Vaccine); saponin adjuvants such as Quil A (U.S. Pat. No. 5,057,540), or particles generated from saponins such as ISCOMs (immunostimulating complexes); chemokines and 15 cytokines, such as interleukins (e.g., IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL 12, etc.), interferons (e.g., gama interferon), macrophage colony stimulating factor (M-CSF), tumor necrosis factor (TNF), defensins 1 or 2, RANTES, MIPI a and MIP-2, etc; muramyl peptides such as N-acetyl-muramyl-L-threonyl-D isoglutamine (thr-MDP), N-acetyl-normuramyl-L (nor 20 IDP), N-acetylmuramyl-alanyl- (1 -2' dipalmitoyl-sn-glycero-3 huydroxyphosphoryloxy)-ethylamine (MTP-PE) etc.; adjuvants derived from the CpG family of molecules, CpG dinucleotides and synthetic oligonucleotides which comprise CpG motifs (see, e.g., Krieg et al. Nature (1995) 374:546, Medzhitov et al. (1997) Curr. Opin. Immunol. 9:4-9, and 25 Davis et al. J Immunol. (1998) 160:870-876) such as TCC ATG ACG TTC CTG ATG CT (SEQ ID NO: 1) and ATC GAC TCT CGA GCG TTC TC (SEQ ID NO: 2); and synthetic adjuvants such as PCPP (Poly[di(carboxylatophenoxy)phosphazene) (Payne et al. Vaccines (1998) 16.92 98). Such adjuvants are commercially available from a number of distributors WO 01/32221 PCT/USOO/30282 -25 such as Accurate Chemicals; Ribi Immunechemicals, Hamilton, MT; GIBCO; Sigma, St. Louis, MO. The adjuvant may delivered individually or delivered in a combination of two or more adjuvants. In this regard, combined adjuvants may have an additive 5 or a synergistic effect in promoting an immune response. A synergistic effect is one where the result achieved by combining two or more adjuvants is greater than one would expect than by merely adding the result achieved with each adjuvant when administered individually. 10 Preparation of Genomic Libraries Genomic libraries can be produced by any method known in the art. A variety of sources can be used for the genomic DNA. Genomic DNA may be commercially available, for example, from sources such as Advanced Biotechnologies Inc (ABI) and Clonetech, Inc. Another standard source is, of 15 course, genomic DNA isolated from an organism (e.g., virus, bacteria, parasite, or other pathogen), a cell (e.g, a cancer cell), or selected tissue. Alternatively, DNA can be prepared from RNA (e.g., RNA viruses) by techniques available in the art. Genomic DNA from the selected source can be isolated by standard procedures, which typically include successive phenol and phenol/chloroform extractions 20 followed by ethanol precipitation. After precipitation, the DNA from an organism, cell or tissue of interest can be treated with a restriction endonuclease which either completely or partially digests the DNA to produce the appropriate fragments. DNA fragments of a selected size can be separated by a number of techniques, including agarose or polyacrylamide gel electrophoresis or pulse field 25 gel electrophoresis (Carle et al. (1984) Nuc. Acid Res. 12:5647-5664; Chu et al. (1986) Science 234:1582; Smith et al. (1987) Methods in Enzymology 151:461), to provide an appropriate size starting material for cloning. Another method for obtaining nucleic acid sequences for use herein is by recombinant means. Thus, a desired nucleotide sequence can be excised from a WO 01/32221 PCT/USOO/30282 -26 vector carrying the same using standard molecular biology procedures. Site specific DNA cleavage can be performed by treating with the suitable restriction enzyme (or enzymes) under conditions which are generally understood in the art, and the particulars of which are specified by manufacturers of commercially 5 available restriction enzymes. If desired, size separation of the cleaved fragments may be performed by polyacrylamide gel or agarose gel electrophoresis using standard techniques. Restriction cleaved fragments may be blunt ended, if desired, by treating with the large fragment of E. coli DNA polymerase I (Klenow) in the presence of 10 the four deoxynucleotide triphosphates (dNTPs) using standard techniques. The Klenow fragment fills in at 5' single-stranded overhangs but digests protruding 3' single strands, even though the four dNTPs are present. If desired, selective repair can be performed by supplying only one, or several, selected dNTPs within the limitations dictated by the nature of the overhang. After Klenow treatment, 15 the mixture can be extracted with e.g. phenol/chloroform, and ethanol precipitated. Treatment under appropriate conditions with S1 nuclease or BAL-31 results in hydrolysis of any single-stranded portion. Once genomic fragments have been prepared or isolated, such sequences can be cloned into any suitable vector construct or replicon. Numerous cloning 20 vectors are known to those of skill in the art, and the selection of an appropriate cloning vector is a matter of choice. In one preferred embodiment, the genomic fragments are cloned into cosmids to generate cosmid libraries. When using cosmid cloning vectors, the fragments are large, preferably between about 20,000 bp (20 kb) and 50,000 base pairs (50 kb) in size (or any integer there between), 25 preferably between about 25 kb and 50 kb, more preferably between about 30-35 kb and 50 kb, and even more preferably between about 35 kb and about 50 kb. Suitable cosmid vectors are commercially available, for example the SuperCos 1 Cosmid Vector Kit (Stratagene, La Jolla, California). Ligation of the DNA into the cosmid is performed as instructed by the manufacturer or may be empirically WO 01/32221 PCT/USOO/30282 -27 determined using methods known in the art in view of the teachings of this specification. In another preferred embodiment, the genomic fragments are cloned into plasmids to generate plasmid libraries. When using plasmid cloning vectors, the 5 fragments are typically between about 5,000 bp (5 kb) and 25,000 base pairs (25 kb) in size (or any integer there between), preferably between about 10 kb and 25 kb, more preferably between about 10-15 kb and 25 kb, and even more preferably between about 15 kb and 20 kb. Suitable plasmid vectors are commercially available. Ligation of the DNA into the plasmid is performed using methods 10 well known in the art in view of the teachings of this specification. As described above, one advantage of the present invention is that the large genomic fragments include endogenous transcription and translation regulatory elements. Such regulatory control sequences include, for example, promoters (a sequence associated with initiating transcription), enhancers (a cis 15 acting sequence that enhances transcription) and other elements including those which cause the expression of a coding sequence to be turned on or off in response to a chemical or physical stimulus, including the presence of a regula tory compound. Thus, in a preferred embodiment, the number of molecular modifications to the vectors and/or inserted polynucleotides is minimal. 20 It is also possible that selected nucleotide sequences within the vector constructs can be placed under the control of heterologous regulatory sequences such as a heterologous promoter, for example when the genomic fragments are derived from bacteria or other prokaryotes, and expression is desired in a eukaryotic subject. Modification of the sequences encoding the particular protein 25 of interest may be desirable to achieve this end. For example, in some cases it may be necessary to modify the sequence so that it is attached to the control sequences with the appropriate orientation; i.e., to maintain the reading frame. The control sequences and other regulatory sequences may be ligated to the coding sequence prior to insertion into a vector. Alternatively, the coding WO 01/32221 PCTIUSOO/30282 -28 sequence can be cloned directly into an expression vector which already contains the control sequences and an appropriate restriction site. Administration of Polynucleotides 5 The genomic fragments and ancillary substances described herein may be administered by any suitable method. In a preferred embodiment, described below, the polynucleotide fragments are administered by coating a suitable construct (e.g., cosmids or plasmids) containing the fragments onto core carrier particles and then administering the coated particles to the subject or cells. 10 However, the genomic fragments may also be delivered using a viral vector or using non-viral systems, e.g., naked nucleic acid delivery. Viral Vectors A number of viral based systems have been used for gene delivery. For example, retroviral systems are known and generally employ packaging lines 15 which have an integrated defective provirus (the "helper") that expresses all of the genes of the virus but cannot package its own genome due to a deletion of the packaging signal, known as the psi sequence. Thus, the cell line produces empty viral shells. Producer lines can be derived from the packaging lines which, in addition to the helper, contain a viral vector which includes sequences required in 20 cis for replication and packaging of the virus, known as the long terminal repeats (LTRs). The genomic fragment(s) of interest can be inserted into the vector and packaged in the viral shells synthesized by the retroviral helper. The recombinant virus can then be isolated and delivered to a subject. (See, e.g., U.S. Patent No. 5,219,740.) Representative retroviral vectors include but are not limited to 25 vectors such as the LHL, N2, LNSAL, LSHL and LHL2 vectors described in e.g., U.S. Patent No. 5,219,740, incorporated herein by reference in its entirety, as well as derivatives of these vectors, such as the modified N2 vector described herein. Retroviral vectors can be constructed using techniques well known in the art. See, e.g., U.S. Patent No 5,219,740; Mann et al. (1983) Cell 33:153-159.
WO 01/32221 PCT/USOO/30282 -29 Adenovirus based systems have been developed for gene delivery and are suitable for delivering the genomic fragments described herein. Human adenoviruses are double-stranded DNA viruses which enter cells by receptor mediated endocytosis. These viruses are particularly well suited for genetic 5 transfer because they are easy to grow and manipulate and they exhibit a broad host range in vivo and in vitro. For example, adenoviruses can infect human cells of hematopoietic, lymphoid and myeloid origin. Furthermore, adenoviruses infect quiescent as well as replicating target cells. Unlike retroviruses which integrate into the host genome, adenoviruses persist extrachromosomally thus 10 minimizing the risks associated with insertional mutagenesis. The virus is easily produced at high titers and is stable so that it can be purified and stored. Even in the replication-competent form, adenoviruses cause only low level morbidity and are not associated with human malignancies. Accordingly, adenovirus vectors have been developed which make use of these advantages. For a description of 15 adenovirus vectors and their uses see, e.g., Haj-Ahmad and Graham (1986) J. Virol. 57:267-274; Bett et al. (1993) J Virol. 67:5911-5921; Mittereder et al. (1994) Human Gene Therapy 5:717-729; Seth et al. (1994) J Virol. 68:933-940; Barr et al. (1994) Gene Therapy 1:51-58; Berkner, K.L. (1988) BioTechniques 6:616-629;Rich et al. (1993) Human Gene Therapy 4:461-476. 20 Adeno-associated viral vectors (AAV) can also be used to administer certain of the smaller genomic fragments (e.g., 5 kb) described herein. AAV vectors can be derived from any AAV serotype, including without limitation, AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAVX7, etc. AAV vectors can have one or more of the AAV wild-type genes deleted in whole or in part, preferably 25 the rep and/or cap genes, but retain one or more functional flanking inverted terminal repeat (ITR) sequences. A functional ITR sequence is generally deemed necessary for the rescue, replication and packaging of the AAV virion. Thus, an AAV vector includes at least those sequences required in cis for replication and packaging (e.g., a functional ITR) of the virus. The ITR need not be the wild- WO 01/32221 PCT/USOO/30282 -30 type nucleotide sequence, and may be altered, e.g., by the insertion, deletion or substitution of nucleotides, so long as the sequence provides for functional rescue, replication and packaging. AAV expression vectors are constructed using known techniques to at 5 least provide as operatively linked components in the direction of transcription, control elements including a transcriptional initiation region, the DNA of interest and a transcriptional termination region. The control elements are selected to be functional in a mammalian cell. The resulting construct which contains the operatively linked components is bounded (5' and 3') with functional AAV ITR 10 sequences. Suitable AAV constructs can be designed using techniques well known in the art. See, e.g., U.S. Patent Nos. 5,173,414 and 5,139,941; International Publication Nos. WO 92/01070 (published 23 January 1992) and WO 93/03769 (published 4 March 1993); Lebkowski et al. (1988) Molec. Cell. Biol. 8:3988-3996; Vincent et al. (1990) Vaccines 90 (Cold Spring Harbor 15 Laboratory Press); Carter, B.J. (1992) Current Opinion in Biotechnology 3:533 539; Muzyczka, N. (1992) Current Topics in Microbiol. and Immunol. 158:97 129; Kotin, R.M. (1994) Human Gene Therapy 5:793-801; Shelling and Smith (1994) Gene Therapy 1:165-169; and Zhou et al. (1994) J Exp. Med. 179:1867 1875. 20 Conventional Pharmaceutical Preparations Formulation of a preparation comprising the genomic DNA fragments of the present invention, with or without addition of an adjuvant composition, can be carried out using standard pharmaceutical formulation chemistries and methodologies all of which are readily available to the ordinarily skilled artisan. 25 For example, compositions containing one or more genomic fragments (e.g., present in a plasmid or cosmid) can be combined with one or more pharmaceutically acceptable excipients or vehicles to provide a liquid preparation.
WO 01/32221 PCTIUSOO/30282 -31 Auxiliary substances, such as wetting or emulsifying agents, pH buffering substances and the like, may be present in the excipient or vehicle. These excipients, vehicles and auxiliary substances are generally pharmaceutical agents that do not induce an immune response in the individual receiving the 5 composition, and which may be administered without undue toxicity. Pharmaceutically acceptable excipients include, but are not limited to, liquids such as water, saline, polyethyleneglycol, hyaluronic acid, glycerol and ethanol. Pharmaceutically acceptable salts can also be included therein, for example, mineral acid salts such as hydrochlorides, hydrobromides, phosphates, sulfates, 10 and the like; and the salts of organic acids such as acetates, propionates, malonates, benzoates, and the like. It is also preferred, although not required, that the preparation will contain a pharmaceutically acceptable excipient that serves as a stabilizer, particularly for peptide, protein or other like molecules if they are to be included in the vaccine composition. Examples of suitable carriers that also 15 act as stabilizers for peptides include, without limitation, pharmaceutical grades of dextrose, sucrose, lactose, trehalose, mannitol, sorbitol, inositol, dextran, and the like. Other suitable carriers include, again without limitation, starch, cellulose, sodium or calcium phosphates, citric acid, tartaric acid, glycine, high molecular weight polyethylene glycols (PEGs), and combination thereof. A 20 thorough discussion of pharmaceutically acceptable excipients, vehicles and auxiliary substances is available in REMINGTON'S PHARMACEUTICAL SCIENCES (Mack Pub. Co., N.J. 1991), incorporated herein by reference. Certain facilitators of nucleic acid uptake and/or expression ("transfection facilitating agents") can also be included in the compositions, for example, 25 facilitators such as bupivacaine, cardiotoxin and sucrose, and transfection facilitating vehicles such as liposomal or lipid preparations that are routinely used to deliver nucleic acid molecules. Anionic and neutral liposomes are widely available and well known for delivering nucleic acid molecules (see, e.g., Liposomes: A Practical Approach, (1990) RPC New Ed., IRL Press). Cationic WO 01/32221 PCT/USOO/30282 -32 lipid preparations are also well known vehicles for use in delivery of nucleic acid molecules. Suitable lipid preparations include DOTMA (N-[1-(2,3 dioleyloxy)propyl]-N,N,N-trimethylammonium chloride), available under the tradename Lipofectin TM , and DOTAP (1,2-bis(oleyloxy)-3 5 (trimethylammonio)propane), see, e.g., Felgner et al. (1987) Proc. Natl. Acad. Sci. USA 84:7413-7416; Malone et al. (1989) Proc. Nati. Acad. Sci. USA 86:6077-6081; US Patent Nos 5,283,185 and 5,527,928, and International Publication Nos WO 90/11092, WO 91/15501 and WO 95/26356. These cationic lipids may preferably be used in association with a neutral lipid, for example 10 DOPE (dioleyl phosphatidylethanolamine). Still further transfection-facilitating compositions that can be added to the above lipid or liposome preparations include spermine derivatives (see, e.g., International Publication No. WO 93/18759) and membrane-permeabilizing compounds such as GALA, Gramicidine S and cationic bile salts (see, e.g., International Publication No. WO 15 93/19768). Alternatively, the nucleic acid molecules of the present invention may be encapsulated, adsorbed to, or associated with, particulate carriers. Suitable particulate carriers include those derived from polymethyl methacrylate polymers, as well as PLG microparticles derived from poly(lactides) and 20 poly(lactide-co-glycolides). See, e.g., Jeffery et al. (1993) Pharm. Res. 10:362 368. Other particulate systems and polymers can also be used, for example, polymers such as polylysine, polyarginine, polyornithine, spermine, spermidine, as well as conjugates of these molecules. The formulated vaccine compositions will thus typically include a 25 polynucleotide (e.g., a plasmid or cosmid) containing at least one genomic fragment from a selected pathogen in an amount sufficient to mount an immunological response. An appropriate effective amount can be readily determined by one of skill in the art. Such an amount will fall in a relatively broad range that can be determined through routine trials. For example, immune WO 01/32221 PCTIUSOO/30282 -33 responses have been obtained using as little as 1 pg of DNA, while in other administrations, up to 2mg of DNA has been used. It is generally expected that an effective dose of polynucleotides containing the genomic fragments will fall within a range of about 1Opg to 1000p g, however, doses above and below this 5 range may also be found effective. The compositions may thus contain from about 0.1% to about 99.9% of the polynucleotide molecules. Administration of Conventional Pharmaceutical Preparations Administration of the above-described pharmaceutical preparations can be effected in one dose, continuously or intermittently throughout the course of 10 treatment. Delivery will most typically be via conventional needle and syringe for the liquid compositions and for liquid suspensions containing particulate compositions. In addition, various liquid jet injectors are known in the art and may be employed to administer the present compositions. Methods of determining the most effective means and dosages of administration are well 15 known to those of skill in the art and will vary with the delivery vehicle, the composition of the therapy, the target cells, and the subject being treated. Single and multiple administrations can be carried out with the dose level and pattern being selected by the attending physician. It should be understood that more than one genomic fragment can be carried by the delivered polynucleotide vector 20 construct. Alternatively, separate vectors (e.g., cosmids or plasmids), each expressing one or more antigens derived from any pathogen can also be delivered to a subject as described herein. Furthermore, it is also intended that the polynucleotides delivered by the methods of the present invention be combined with other suitable compositions 25 and therapies. For instance, in order to augment an immune response in a subject, the compositions and methods described herein can further include ancillary substances (e.g., adjuvants), such as pharmacological agents, cytokines, or the like. Ancillary substances may be administered, for example, as proteins or other macromolecules at the same time, prior to, or subsequent to, WO 01/32221 PCT/USOO/30282 -34 administration of the DNA vaccines (e.g., cosmids or plasmids) described herein. The nucleic acid molecule compositions may also be administered directly to the subject or, alternatively, delivered ex vivo, to cells derived from the subject, using methods known to those skilled in the art. 5 Coated Particles In one embodiment, constructs containing the genomic fragments (e.g, plasmids or cosmids), and other ancillary components such as adjuvants are delivered using carrier particles. Particle-mediated delivery methods for administering such nucleic acid preparations are known in the art. Thus, once 10 prepared and suitably purified, the above-described plasmid and cosmid constructs can be coated onto carrier particles (e.g., core carriers) using a variety of techniques known in the art. Carrier particles are selected from materials which have a suitable density in the range of particle sizes typically used for intracellular delivery from an appropriate particle delivery device. The optimum 15 carrier particle size will, of course, depend upon the diameter of the target cells. For the purposes of the present invention, tungsten, gold, platinum and iridium core carrier particles can be used. Tungsten and gold particles are preferred. Tungsten particles are readily available in average sizes of 0.5 to 2.0 pm in diameter. Although such particles have optimal density for use in particle 20 delivery methods, and allow highly efficient coating with DNA, tungsten may potentially be toxic to certain cell types. Accordingly, gold particles or microcrystalline gold (e.g., gold powder Al 570, available from Engelhard Corp., East Newark, NJ) will also find use with the present methods. Gold particles provide uniformity in size (available from Alpha Chemicals in particle sizes of 1 25 3 tm, or available from Degussa, South Plainfield, NJ in a range of particle sizes including 0.95 tm) and reduced toxicity. A number of methods are known and have been described for coating or precipitating DNA or RNA onto gold or tungsten particles. Most such methods generally combine a predetermined amount of gold or tungsten with plasmid WO 01/32221 PCT/USOO/30282 -35 DNA, CaCl 2 and spermidine. The resulting solution is vortexed continually during the coating procedure to ensure uniformity of the reaction mixture. After precipitation of the nucleic acid, the coated particles can be transferred to suitable membranes and allowed to dry prior to use, coated onto surfaces of a sample 5 module or cassette, or loaded into a delivery cassette for use in a suitable particle delivery device. Peptide adjuvants (e.g., cytokines and bacterial toxins), can also be coated onto the same or similar core carrier particles. For example, peptides can be attached to a carrier particle by simply mixing the two components in an 10 empirically determined ratio, by ammonium sulfate precipitation or other solvent precipitation methods familiar to those skilled in the art, or by chemical coupling of the peptide to the carrier particle. The coupling of L-cysteine residues to gold has been previously described (Brown et al., Chemical Society Reviews 9:27 1 311 (1980)). Other methods would include, for example, dissolving the peptide 15 adjuvant in absolute ethanol, water, or an alcohol/water mixture, adding the solution to a quantity of carrier particles, and then drying the mixture under a stream of air or nitrogen gas while vortexing. Alternatively, the adjuvant can be dried onto carrier particles by centrifugation under vacuum. Once dried, the coated particles can be resuspended in a suitable solvent (e.g., ethyl acetate or 20 acetone), and triturated (e.g., by sonication) to provide a substantially uniform suspension. The core carrier particles coated with the adjuvant can then be combined with core carrier particles carrying the genomic fragment constructs and administered in a single particle injection step, or administered separately from the genomic fragment compositions. 25 Administration of Coated Particles Following their formation, core carrier particles coated with the nucleic acid preparations of the present invention, alone or in combination with e.g., adjuvant preparations, are delivered to a subject using particle-mediated delivery techniques.
WO 01/32221 PCT/USOO/30282 -36 Various particle delivery devices suitable for particle-mediated delivery techniques are known in the art, and are all suited for use in the practice of the invention. Current device designs employ an explosive, electric or gaseous discharge to propel the coated core carrier particles toward target cells. The 5 coated particles can themselves be releasably attached to a movable carrier sheet, or removably attached to a surface along which a gas stream passes, lifting the particles from the surface and accelerating them toward the target. An example of a gaseous discharge device is described in U.S. Patent No. 5,204,253. An explosive-type device is described in U.S. Patent No. 4,945,050. One example of 10 an electric discharge-type particle acceleration apparatus is described in U.S. Patent No. 5,120,657. Another electric discharge apparatus suitable for use herein is described in U.S. Patent No. 5,149,655. The disclosure of all of these patents is incorporated herein by reference in their entireties. The coated particles are administered to the subject to be treated in a 15 manner compatible with the dosage formulation, and in an amount that will be effective to bring about a desired immune response. The amount of the composition to be delivered which, in the case of nucleic acid molecules is generally in the range of from 0.001 to 100.0 ig, more typically 0.01 to 10.0 pg of nucleic acid molecule per dose, and in the case of peptide or protein molecules 20 is 1 pg to 5 mg, more typically 1 to 50 tg of peptide, depends on the subject to be treated. The exact amount necessary will vary depending on the age and general condition of the individual being immunized and the particular nucleotide sequence or peptide selected, as well as other factors. An appropriate effective amount can be readily determined by one of skill in the art upon reading the 25 instant specification. Thus, an effective amount of the genomic fragments herein described will be sufficient to bring about a suitable immune response in an immunized subject, and will fall in a relatively broad range that can be determined through routine trials. Preferably, the coated core particles are delivered to suitable recipient cells WO 01/32221 PCT/USOO/30282 -37 in order to bring about an immune response (e.g., T-cell activation) in the treated subject. Particulate Compositions Alternatively, the genomic fragments of the present invention (e.g. 5 plasmid or cosmid constructs carrying the genomic fragments), as well as one or more selected adjuvants, can be formulated as a particulate composition. More particularly, formulation of particles comprising a genomic fragment of interest can be carried out using standard pharmaceutical formulation chemistries and methodologies all of which are readily available to the reasonably skilled artisan. 10 For example, one or more vector construct and/or adjuvants can be combined with one or more pharmaceutically acceptable excipients or vehicles to provide a vaccine composition. Auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present in the excipient or vehicle. These excipients, vehicles and auxiliary substances are generally 15 pharmaceutical agents that do not themselves induce an immune response in the individual receiving the composition, and which may be administered without undue toxicity. Pharmaceutically acceptable excipients include, but are not limited to, liquids such as water, saline, polyethyleneglycol, hyaluronic acid, glycerol and ethanol. Pharmaceutically acceptable salts can be included therein, 20 for example, mineral acid salts such as hydrochlorides, hydrobromides, phosphates, sulfates, and the like; and the salts of organic acids such as acetates, propionates, malonates, benzoates, and the like. It is also preferred, although not required, that the nucleic acid composition will contain a pharmaceutically acceptable carrier that serves as a stabilizer, particularly for peptide, protein or 25 other like adjuvants or ancillary materials. Examples of suitable carriers that also act as stabilizers for peptides include, without limitation, pharmaceutical grades of dextrose, sucrose, lactose, trehalose, mannitol, sorbitol, inositol, dextran, and the like. Other suitable carriers include, again without limitation, starch, cellulose, sodium or calcium phosphates, citric acid, tartaric acid, glycine, high WO 01/32221 PCT/USOO/30282 -38 molecular weight polyethylene glycols (PEGs), and combination thereof. A thorough discussion of pharmaceutically acceptable excipients, carriers, stabilizers and other auxiliary substances is available in REMINGTONS PHARMACEUTICAL SCIENCES (Mack Pub. Co., N.J. 1991), incorporated 5 herein by reference. The formulated compositions will include an amount of the genomic fragment of interest which is sufficient to mount an immunological response, as defined above. An appropriate effective amount can be readily determined by one of skill in the art. Such an amount will fall in a relatively broad range, 10 generally within the range of about 0.1 pg to 25 mg or more of the nucleic acid construct of interest, and specific suitable amounts can be determined through routine trials. The compositions may contain from about 0.1% to about 99.9% of the nucleic acid molecule. If an adjuvant is included in the composition, or the methods are used to provide a particulate adjuvant composition, the adjuvant will 15 be present in a suitable amount as described above. The compositions are then prepared as particles using standard techniques, such as by simple evaporation (air drying), vacuum drying, spray drying, freeze drying lyophilizationn), spray freeze drying, spray coating, precipitation, supercritical fluid particle formation, and the like. If desired, the resultant particles can be densified using the 20 techniques described in commonly owned International Publication No. WO 97/48485, incorporated herein by reference. Single unit dosages or multidose containers, in which the particles may be packaged prior to use, can comprise a hermetically sealed container enclosing a suitable amount of the particles comprising a suitable nucleic acid construct (e.g., 25 a plasmid or cosmid) and/or the selected adjuvant (e.g., to provide a vaccine composition). The particulate compositions can be packaged as a sterile formulation, and the hermetically sealed container can thus be designed to preserve sterility of the formulation until use in the methods of the invention. If desired, the containers can be adapted for direct use in a particle delivery device.
WO 01/32221 PCT/USOO/30282 -39 Such containers can take the form of capsules, foil pouches, sachets, cassettes, and the like. Appropriate particle delivery devices (e.g., needleless syringes) are described herein. The container in which the particles are packaged can further be labelled 5 to identify the composition and provide relevant dosage information. In addition, the container can be labelled with a notice in the form prescribed by a governmental agency, for example the Food and Drug Administration, wherein the notice indicates approval by the agency under Federal law of the manufacture, use or sale of the antigen, adjuvant (or vaccine composition) contained therein for 10 human administration. The particulate compositions (comprising one or more genomic fragments of interest alone, or in combination with a selected adjuvant) can then be administered using a transdermal delivery technique. Preferably, the particulate compositions will be delivered via a powder injection method, e.g., delivered 15 from a needleless syringe system such as those described in commonly owned International Publication Nos. WO 94/24263, WO 96/04947, WO 96/12513, and WO 96/20022, all of which are incorporated herein by reference. Delivery of particles from such needleless syringe systems is typically practised with particles having an approximate size generally ranging from 0.1 to 250 gm, 20 preferably ranging from about 10-70 pim. Particles larger than about 250 um can also be delivered from the devices, with the upper limitation being the point at which the size of the particles would cause untoward damage to the skin cells. The actual distance which the delivered particles will penetrate a target surface depends upon particle size (e.g., the nominal particle diameter assuming a 25 roughly spherical particle geometry), particle density, the initial velocity at which the particle impacts the surface, and the density and kinematic viscosity of the targeted skin tissue. In this regard, optimal particle densities for use in needleless injection generally range between about 0.1 and 25 g/cm 3 , preferably between about 0.9 and 1.5 g/cm 3 , and injection velocities generally range between about WO 01/32221 PCT/USOO/30282 -40 100 and 3,000 m/sec, or greater. With appropriate gas pressure, particles having an average diameter of 10-70 im can be accelerated through the nozzle at velocities approaching the supersonic speeds of a driving gas flow. If desired, these needleless syringe systems can be provided in a 5 preloaded condition containing a suitable dosage of the particles comprising the genomic fragments and/or the selected adjuvant. The loaded syringe can be packaged in a hermetically sealed container, which may further be labelled as described above. Thus, the method can be used to obtain nucleic acid particles having a size 10 ranging from about 10 to about 250 gm, preferably about 10 to about 150 pim, and most preferably about 20 to about 60 gm; and a particle density ranging from about 0.1 to about 25 g/cm 3 , and a bulk density of about 0.5 to about 3.0 g/cm 3 , or greater. Similarly, particles of selected adjuvants having a size ranging from about 15 0.1 to about 250 gm, preferably about 0.1 to about 150 pm, and most preferably about 20 to about 60 pm; a particle density ranging from about 0.1 to about 25 g/cm 3 , and a bulk density of preferably about 0.5 to about 3.0 g/cm 3 , and most preferably about 0.8 to about 1.5 g/cm 3 can be obtained. Administration of Particulate Compositions 20 Following their formation, the particulate compositions (e.g., powder) can be delivered transdermally to the tissue of a vertebrate subject using a suitable transdermal delivery technique. Various particle delivery devices suitable for administering the substance of interest are known in the art, and will find use in the practice of the invention. A particularly preferred transdermal particle 25 delivery system employs a needleless syringe to fire solid particles in controlled doses into and through intact skin and tissue. See, e.g., U.S. Patent No. 5,630,796 to Bellhouse et al. which describes a needleless syringe (also known as "the PowderJect@ particle delivery device"). Other needleless syringe configurations are known in the art and are described herein.
WO 01/32221 PCTIUSOO/30282 -41 Compositions containing a therapeutically effective amount of the powdered molecules described herein can be delivered to any suitable target tissue via the above-described particle delivery devices. For example, the compositions can be delivered to muscle, skin, brain, lung, liver, spleen, bone 5 marrow, thymus, heart, lymph, blood, bone cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland and connective tissues. For nucleic acid molecules, delivery is preferably to, and the molecules expressed in, terminally differentiated cells; however, the molecules can also be delivered to non-differentiated, or partially differentiated 10 cells such as stem cells of blood and skin fibroblasts. The powdered compositions are administered to the subject to be treated in a manner compatible with the dosage formulation, and in an amount that will be prophylactically and/or therapeutically effective. The amount of the composition to be delivered, generally in the range of from 0.5 pg/kg to 100 15 ptg/kg of nucleic acid molecule per dose, depends on the subject to be treated. Doses for other pharmaceuticals, such as physiological active peptides and proteins, generally range from about 0.1 pig to about 20 mg, preferably 10 pg to about 3 mg. The exact amount necessary will vary depending on the age and general condition of the individual to be treated, the severity of the condition 20 being treated, the particular preparation delivered, the site of administration, as well as other factors. An appropriate effective amount can be readily determined by one of skill in the art. Thus, a "therapeutically effective amount" of the present particulate compositions will be sufficient to bring about treatment or prevention of disease 25 or condition symptoms, and will fall in a relatively broad range that can be determined through routine trials.
WO 01/32221 PCTIUSOO/30282 -42 Below are examples of specific embodiments for carrying out the present invention. The examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way. 5 EXAMPLES Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperatures, etc.), but some experimental error and deviation should, of course, be allowed for. 10 Example 1: Nucleic Acid Immunization Using HSV-2 cosmids In order to assess the specificity and effectiveness of nucleic acid immunization using DNA vaccine cosmids containing HSV-2 genomic DNA, the 15 following studies were carried out. A. Cosmid Preparation HSV-2 Cosmids: HSV-2 genomic DNA was obtained by infecting Vero cells (ATCC # 20 CCL-8 1) with HSV-2 strain MS (ATCC # VR-54T) and isolating genomic DNA from the infected cells. Cosmids containing fragments of the HSV-2 genome were generated by digesting HSV-2 genomic DNA, as described above, with the restriction enzyme EcoRI (New England Biolabs). As shown in Figure 1, the HSV genome has been mapped and contains at least 10 EcoR1 sites, indicated in 25 the figure with arrows. The digested DNA was ligated into cosmids using the SuperCos 1 Cosmid Vector Kit from Stratagene following the manufacturers instructions. Positive cosmids were first identified from the fragment sizes generated by an EcoRI digest of purified cosmid DNA. The digested DNA was loaded onto a 1 % agarose gel (15 hour pulse field electrolysis, run time at WO 01/32221 PCT/USOO/30282 -43 6V/cm, 120' angle, 14C in 0.5 X TBE buffer). Further identification was based on restriction maps generated with other restriction enzymes. This preliminary analysis was used to determine fragment locations relative to the HSV-2 genome shown in Figure 1. For example, cosmid #68 contains a fragment of the HSV-2 5 genome extending from the 7th to 10th EcoRI sites shown, while clone #74 contains an HSV-2 fragment extending from the 1st through 4th depicted EcoR1 sites. B. Preparation of coated microparticles 10 Cosmid DNA was coated onto 1-3 ym gold particles (Degussa Corp., South Plainfield, NJ) using techniques described by Eisenbraun et al. (1993) DNA Cell Biol. 12:791-797. Briefly, cosmid DNA was affixed to gold particles by adding 13.26 mg of 1-3 micron gold powder (Degussa) and an appropriate amount of cosmid DNA (2 pug per mg of gold powder) to a 1.5 ml centrifuge tube 15 containing 500 gI of 0.05 M spermidine (Sigma). Cosmid DNA and gold were coprecipitated by the addition of 500 pl of 10% CaCl 2 (Fujisawa) dropwise while vortexing, after which the precipitate was allowed to settle for several minutes. The gold/DNA precipitate was concentrated by centrifugation in a microcentrifuge for 15 seconds, washed three time in absolute ethanol (Spectrum) 20 and resuspended in an appropriate amount of ethanol (8.84 mg gold powder/ml of ethanol) and polyvinyl pyrrilodine (PVP) (Spectrum) 0.05 mg/ml of ethanol. The suspension was then transferred to a glass vial which was capped and immersed in a sonicating water bath for 2-5 seconds to resolve clumps. The ethanol solution was then injected into Tefzel tubing (McMaster-Carr) and the gold/DNA 25 adhered to the side of the tubing using centrifugal force. The remaining ethanol was then ejected using a small, controlled flow of nitrogen gas. The tube was then dried for one hour with a flow of nitrogen gas, and then cut into half inch cartridges. The cartridges were stored in a tightly capped glass scintillation vials with dessicant at 4'C until use.
WO 01/32221 PCT/USOO/30282 -44 The DNA-coated gold particles were then loaded into Tefzel@ tubing as described in U.S. Patent No. 5,584,807 to McCabe, and the tubing was cut into 1.27 cm lengths to serve as cartridges in a particle delivery device. The helium-pulse PowderJect@ XR particle delivery device has been previously 5 described (see, U.S. Patent No. 5,584,807) and was obtained from PowderJect Vaccines, Madison, WI. In the vaccinations, each 1.27 cm cartridge nominally contained 0.5 mg gold particles coated with 1 ptg of DNA. C. Immunizations 10 Balb/c mice were immunized by particle-mediated delivery using a single shot of gold beads coated with cosmid (approximately 1 pig cosmid/mg gold, 0.5 mg gold delivered per shot). Animals were boosted 4 weeks after priming. Serum was collected at the time of boosting (4 week) and two weeks later (6 week). 15 Serum antibody levels in mice at 6 weeks were detected using an ELISA. Briefly, HSV-2 antigen was prepared at a concentration of 10 Ig/ml in PBS. One hundred microliters of the HSV-2 antigen preparation was added to each well of a 96 well plates (Costar), for a concentration of approximate 1 pig of protein/well. The plates were incubated overnight at 4'C and then washed 3 times with 20 PBS/0.05% Tween 20 solution. The plates were blocked with PBS/Tween with 5% dry milk for 1 hour at room temperature. Dilute rabbit anti-HSV-2 (control) antibody or mouse serum (unknowns) at 1:100 in PBS/Tween was added to appropriate wells. The plates were washed 3 times with PBS/0.05% Tween 20. A 1:8000 dilution of biotin conjugated goat anti-rabbit in PBS/Tween was 25 prepared and 100 pl added to each well. The plates were washed 3 times with PBS/0.05% Tween 20. A 1:8000 dilution of streptavidin-HRP was prepared, 100 ptl added to each well for a 1 hour incubation at room temperature. The plates were washed 6 times with PBS/0.05% Tween 20. TMB was prepared just prior to use, 100 pl added to each well and incubated for 15 at room temperature.
WO 01/32221 PCT/USOO/30282 -45 Reactions were stopped by the addition of 100 gl 1 N H 2
SO
4 and optical density values read on an automated plate reader at 450 nm. Values from the 1:160 dilution were averaged for the individual animals (4 per group) and the optical density of the control group (animals vaccinated with empty vector) was 5 subtracted. Results for particular cosmids are shown in Figure 2. The numbers above the bars are the names of the different cosmid clones. D. Cell Mediated immune Response Spleen cell proliferation assays were done to further assess the ability of 10 an HSV-2 genome-derived cosmid to induce a cell-mediated immune (CMI) response. This assay measures the capacity of spleen-derived lymphocytes cultured in vitro to proliferate, i.e., grow and divide thus increasing in number, in response to HSV-2 antigens. The greater the amount of proliferation, as assessed by a higher stimulation index score, the stronger the immune response against the 15 antigens. BALB/c mice were immunized with either a plasmid containing the gene for expression of the HSV-2 gD-antigen PCR amplified from HSV-2 genomic DNA cloned into a pTarget vector (Promega), or with a HSV-2 genomic-derived cosmid (designated No. 68 as described above). A PowderJect @ XR particle 20 delivery device was used to vaccinate the mice by delivery of plasmid/cosmid DNA-coated gold-particles into the epidermis. Mice were immunized with a prime and two boosts (each given 4 weeks apart). Each immunization consisted of a single injection that delivered 1 pg of DNA/0.5 mg gold. These mice had also been injected in their ear pinna with protein extracts (100 pg in PBS), 1-2 25 weeks after the third boost immunization, to assess their ability to mount a delayed-type hypersensitivity response. The right and left ears of these animals were injected with protein extracts derived from HSV-2 infected and uninfected cultured VERO cells (ATCC #CCL-81), respectively.
WO 01/32221 PCT/USOO/30282 -46 Three weeks after protein injection two mice were sacrificed from each immunization group (designated in the figure legend-box as "gD Plasmid and Cosmid #68"), along with two non-immune nalve mice. The spleen cells from these animals were isolated and cultured in vitro with either pure gD protein (0.1 5 pig/well), or HSV-2 infected VERO cell protein extract (25 or 10 pig/well), or no added antigen. After 3 days in culture the antigen induced proliferation responses of the different spleen cell populations were quantified by the amount of radioactively labeled thymidine that was incorporated into the dividing cells (measured as counts per minute in a scintillation counter). Stimulation indices 10 were calculated by dividing the amount of radioactivity, i.e., counts per minute (cpm), incorporated within antigen-stimulated spleen cells by the cpm of their non-antigen-stimulated spleen cell counterparts. In Figure 3, the stimulation indices of the antigen-stimulated non-immune naive spleen cells were subtracted from that of the spleen cells derived from the immunized mice to give a true 15 representation of the level of antigen-specific cell-mediated immunity elicited by the gD-antigen expressing plasmid compared to that elicited by the HSV-2 genomic-derived cosmid. These results clearly demonstrate that the HSV-2 genomic-derived cosmid #68 is capable of eliciting a strong CMI response against HSV-2 antigens in 20 mice. The CMI response to gD protein was slightly higher for spleen cells obtained from gD plasmid immunized mice compared to that of spleen cells obtained from mice immunized with cosmid #68. In contrast, the CMI response to protein extract from HSV-2 infected VERO cells, which contains a multiple array of HSV-2 antigens, was significantly higher for the spleens cells obtained 25 from the mice immunized with cosmid #68 compared to that of the spleen cells obtained from the mice immunized with the single gD-antigen expressing plasmid. Thus, these data demonstrate the utility of using a cosmid-based DNA vaccine to produce a stronger CMI response.
WO 01/32221 PCT/USOO/30282 -47 Similarly experiments were carried out with above-described HSV-2 genomic-derived cosmids in a guinea pig animal model system. The cosmids also elicited a strong CMI response in these animals. In subsequent challenge studies in the immunized guinea pigs, protective immunity was not observed; 5 however, these results were deemed inconclusive. Example 2: Nucleic Acid Immunization Using HSV-2 Plasmids A. Plasmid construction HSV-2 genomic DNA was obtained by infecting VERO cells (ATCC 10 #CCL-81) with HSV-2 strain MS (ATCC #VR-54T) and isolating genomic DNA from purified viral particles. PCR was performed using the genomic DNA to amplify segments for cloning into a plasmid vector. The primer gB2, having the following sequence: CGC GTC TAG AAA CGT TCG CGA CCA CGG GTG AC (SEQ ID NO: 3) and primer gB3, having 15 the following sequence: CGC GTC TAG ATG ATG GGG TCC CGC TAA CTC GC (SEQ ID NO: 4), which correspond to sequences at 58160 and 52930 of the HSV-2 genome, respectively, were used to amplify a product of approximately 5200 bp by PCR. A second PCR product was generated with using primer gB2 (SEQ ID NO: 3) and primer gB4, having the following sequence: CGC GTC 20 TAG ACC TTC ATG ACC GCG CTG GTC CT (SEQ ID NO: 5) which correspond to sequences at 58160 and 49670, respectively, of the HSV-2 genome. This produced a product of approximately 8500 bp. Both products contain the genomic sequences coding for the glycoprotein B protein. The PCR cycle specifications were: 98 C 30 seconds, 70'C 10 minutes, 25 for 35 cycles. PCR reactions were carried out using the Expand Long template PCR system (Boehringer Mannheim). Reaction conditions were 20 pmoles of each primer, 1 tg of HSV-2 genomic DNA, IX buffer #1 (5 mM Tris-HCl, pH 9.2, 1.6 mM (NH 4
)
2
SO
4 , 1.75 mM MgCl 2 ), 200 gM deoxynucleotides (dNTPs, Sigma), 1% DMSO, 10 mM MgSO 4 , H 2 0 to 50 pL and 1U of Expand DNA WO 01/32221 PCT/USOO/30282 -48 polymerase. PCR products were "A-tailed" by incubating the products with 1U Taq DNA polymerase (Promega) for 10 minutes at 72 C after the addition of an additional 100 gM dNTPs. The PCR fragments were purified from agarose gels and ligated into pGEM-T Easy vector system (Promega) using manufacturers 5 instructions. TOP 10 E. coli competent bacteria (Stratagene) were transformed with the ligation mixtures by electroporation and bacteria retaining plasmid were isolated on agar plates prepared with ampicillin. DNA minipreps were made from overnight cultures of selected bacterial colonies and purified plasmids were tested for the desired inserts. Mobility on agarose gels and an appropriate 10 restriction pattern was used to identify positive plasmids. B. Preparation of coated microparticles Plasmid DNA was coated onto 1-3 yim gold particles (Degussa Corp., South Plainfield, NJ) using techniques described by Eisenbraun et al. (1993) DNA 15 Cell Biol. 12:791-797. Briefly, plasmid DNA was affixed to gold particles by adding gold powder and an appropriate amount of plasmid DNA to a centrifuge tube containing spermidine. Plasmid DNA and gold were coprecipitated by the addition of CaCl 2 (Fujisawa) dropwise while vortexing, after which the precipitate was allowed to settle for several minutes. The gold/DNA precipitate 20 was concentrated by centrifugation in a microcentrifuge, washed three time in absolute ethanol and resuspended in an appropriate amount of ethanol and polyvinyl pyrrilodine (PVP). The suspension was then transferred to a glass vial which was capped and immersed in a sonicating water bath for 2-5 seconds to resolve clumps. The ethanol solution was then injected into Tefzel@ tubing 25 (McMaster-Carr) and the gold/DNA adhered to the side of the tubing using centrifugal force. The remaining ethanol was then removed using a small, controlled flow of nitrogen gas. The tube was then dried for with a flow of nitrogen gas, and then cut into cartridges. The cartridges were stored in a tightly capped glass scintillation vials with dessicant at 4'C until use.
WO 01/32221 PCTIUSOO/30282 -49 C. Immunizations C57/black mice were immunized by particle-mediated delivery using a single shot of gold beads coated with plasmid (approximately 2 ptg plasmid/mg 5 gold, 0.5 mg gold delivered per shot). Animals are boosted 4 weeks after priming. Serum is collected at the time of boosting (4 week) and is also collected two weeks later (6 week). Serum antibody levels in mice at 6 weeks is detected using an ELISA substantially identical to that described in Example 1 above. Spleen cell 10 proliferation assays are also carried out to further assess the ability of an HSV-2 genome-derived plasmid to induce a cell-mediated immune (CMI) response. Thus, this study demonstrates the utility of using a plasmid-based DNA vaccine to elicit an immune response. 15 Accordingly, novel compositions for eliciting an immune response have been described. Methods of using these compositions have also been described. Although preferred embodiments of the subject invention have been described in some detail, it is understood that obvious variations can be made without departing from the spirit and the scope of the invention as defined by the 20 appended claims.
Claims (38)
1. Use of a genetic construct carrying a genomic DNA fragment at least 5 kb in size from a pathogen in the manufacture of a medicament for 5 eliciting an immune response in a vertebrate subject by administering the said construct to the subject whereby antigen encoded by a sequence contained in said genomic DNA fragment is expressed in an amount sufficient to elicit an immune response. 10
2. Use according to claimI, wherein expression of coding sequences contained within the said genomic fragment is not driven by a heterologous promoter.
3. Use according to claim 1 or 2, wherein the construct is a 15 plasmid carrying a said genomic fragment of 5 kb to 25 kb in size.
4. Use according to claim 1 or 2, wherein the construct is a cosmid carrying a said genomic fragment of at least 25 kb in size. 20
5. Use according to claim 4, wherein the genomic DNA fragment is between about 35 kb and about 50 kb in size.
6. Use according to any one of the preceding claims, wherein the construct carries genomic fragments from two or more pathogens. 25
7. Use according to any one of the preceding claims, wherein the pathogen is a bacteria.
8. Use according to any one of the preceding claims, wherein the 30 pathogen is a virus. WO 01/32221 PCT/USOO/30282 -51
9. Use according to claim 6, wherein the genomic fragments are from more than one virus.
10. Use according to any one of the preceding claims, wherein the 5 construct is administered by transdermal administration.
11. Use according to claim 10, wherein the construct is provided on a core carter. 10
12. Use of a genetic construct carrying genomic DNA fragments at least 5 kb in size encoding antigens from one or more pathogens in the manufacture of a medicament for eliciting an immune response in a vertebrate subject, wherein the genetic construct is coated on a core carrier and the coated core carrier is administered to the subject using a transdermal particle 15 mediated delivery technique, and further wherein antigen encoded by a coding sequence present in the genomic fragments is expressed in the subject in an amount sufficient to elicit an immune response.
13. Use according to claim 12, wherein expression of coding 20 sequences contained within the said genomic fragment is not driven by a heterologous promoter.
14. Use according to claim 12 or 13, wherein the construct is a plasmid carrying a said genomic fragment of from 5 kb to 25 kb in size. 25
15. Use according to claim 12 or 13, wherein the construct is a cosmid carrying a said genomic fragment of at least 25 kb in size.
16. Use according to any one of claims 12 to 15, wherein genomic 30 DNA fragments are derived from two or more pathogens. WO 01/32221 PCT/USOO/30282 -52
17. Use according to any one of claims 12 to 16, wherein the pathogen is a virus.
18. Use according to any one of claims 12 to 17, wherein the 5 genomic DNA fragments are derived from two or more viruses.
19. Use according to any one of claims 12 to 17, wherein the pathogen is a bacteria. 10
20. Use according to any one of claims 12 to 19, wherein the said administration is repeated to provide a prime and a booster administration.
21. Use according to any one of claims 12 to 20, wherein the core carrier has an average diameter of about 0.5 to about 5 4m and a density 15 sufficient to allow delivery into the subject.
22. Use according to any one of claims 12 to 21, wherein the core carrier is comprised of a metal. 20
23. Use according to claim 22, wherein the metal is gold.
24. Use of a genetic construct carrying genomic DNA fragments at least 5 kb in size from one or more pathogens in the manufacture of a composition for identifying a sequence encoding an antigenic polypeptide by 25 administering the said construct to a subject, wherein the genomic DNA fragments contain a coding sequence for said antigenic polypeptide and, upon delivery, the antigenic polypeptide is expressed in an amount sufficient to elicit an immune response; and identifying the sequence on the construct encoding the antigenic polypeptide. 30 WO 01/32221 PCT/US00/30282 -53
25. Use according to claim 24, wherein expression of coding sequences contained within the said genomic fragment is not driven by a heterologous promoter. 5
26. Use according to claim 24 or 25, wherein the construct is a plasmid carrying a said genomic fragment of from 5 kb to 25 kb in size.
27. Use according to claim 24 or 25, wherein the construct is a cosmid carrying a said genomic fragment of at least 25 kb in size. 10
28. Use according to any one of claims 24 to 27, wherein the sequence encoding the antigenic polypeptide is identified by administering one or more said fragments of the genetic construct and identifying which fragment contains the sequence encoding the antigenic polypeptide. 15
29. Use according to any one of claims 24 to 27, wherein the sequence encoding the antigenic polypeptide is identified by sequencing the genetic construct. 20
30. A vaccine composition comprising one or more constructs carrying genomic DNA fragments from one or more pathogens, wherein the genomic fragments are of at least 5 kb in size and contain at least one antigen coding sequence. 25
31. A vaccine composition according to claim 30, wherein expression of coding sequences contained within the said genomic fragment is not driven by a heterologous promoter. WO 01/32221 PCT/USOO/30282 -54
32. A vaccine composition comprising one or more nucleic acid constructs carrying genomic DNA fragments from herpes simplex virus-2 (HSV-2). 5
33. A vaccine composition according to claim 32, wherein expression of coding sequences contained within the said genomic fragment is not driven by a heterologous promoter.
34. A vaccine composition according to claim 32 or 33, wherein 10 the genomic DNA fragment from HSV-2 contains a sequence substantially homologous to the sequence extending from the 7th to 10th EcoR1 sites shown in the HSV-2 genome map of Figure 1.
35. A method for eliciting an immune response in a vertebrate 15 subject, said method comprising administering nucleic acid constructs carrying genomic DNA fragments of at least 5 kb in size, wherein the genomic fragments have been derived or obtained from one or more pathogens and the constructs are administered to the subject in an amount sufficient to elicit an immune response against antigen encoded by a sequence contained in the said 20 genomic DNA fragments.
36. A method for eliciting an immune response in a vertebrate subject, said method comprising: (a) providing a core carrier coated with construct carrying genomic 25 DNA fragments derived or obtained from one or more pathogens, wherein the genomic fragments contain an antigen coding sequence and are greater than 5 kb in size; and (b) administering the coated core carrier to the subject using a particle-mediated transdermal delivery technique, whereby antigen encoded by WO 01/32221 PCT/USOO/30282 -55 a coding sequence present in the genomic fragments is expressed in the subject in an amount sufficient to elicit an immune response.
37. A method of identifying a sequence encoding an antigenic 5 polypeptide, the method comprising: (a) administering one or more constructs carrying genomic DNA fragments at least 5 kb in size and obtained or derived from one or more pathogens, wherein the genomic fragments contain a coding sequence for said antigenic polypeptide and, upon delivery, the antigenic polypeptide is 10 expressed from said coding sequence in an amount sufficient to elicit an immune response; and (b) identifying the coding sequence on the construct which encodes the antigenic polypeptide. 15
38. A method according to any one of claims 35 to 37, wherein expression of coding sequences contained within the said genomic fragment is not driven by a heterologous promoter. 20
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43236199A | 1999-11-03 | 1999-11-03 | |
US09/432361 | 1999-11-03 | ||
PCT/US2000/030282 WO2001032221A1 (en) | 1999-11-03 | 2000-11-02 | Dna-vaccines based on constructs derived from the genomes of human and animal pathogens |
Publications (2)
Publication Number | Publication Date |
---|---|
AU1359101A true AU1359101A (en) | 2001-05-14 |
AU785066B2 AU785066B2 (en) | 2006-09-14 |
Family
ID=23715822
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU13591/01A Ceased AU785066B2 (en) | 1999-11-03 | 2000-11-02 | DNA-vaccines based on constructs derived from the genomes of human and animal pathogens |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1225920A1 (en) |
JP (1) | JP2003528816A (en) |
CN (1) | CN1409641A (en) |
AU (1) | AU785066B2 (en) |
CA (1) | CA2389693A1 (en) |
IL (1) | IL149413A0 (en) |
NZ (1) | NZ538837A (en) |
WO (1) | WO2001032221A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100863823B1 (en) * | 1999-12-22 | 2008-10-15 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Cosmid DNA Constructs and Methods of Making and Using the Same |
JP5872755B2 (en) | 2006-07-20 | 2016-03-01 | バイカル インコーポレイテッド | Compositions and methods for anti-HSV-2 vaccination |
CN112618709B (en) * | 2019-09-24 | 2023-11-03 | 华南理工大学 | Pig oral vaccination slow-release adjuvant and preparation method and application thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5703057A (en) * | 1995-04-07 | 1997-12-30 | Board Of Regents The University Of Texas System | Expression library immunization |
-
2000
- 2000-11-02 IL IL14941300A patent/IL149413A0/en unknown
- 2000-11-02 WO PCT/US2000/030282 patent/WO2001032221A1/en active Application Filing
- 2000-11-02 NZ NZ538837A patent/NZ538837A/en unknown
- 2000-11-02 CN CN00816887A patent/CN1409641A/en active Pending
- 2000-11-02 EP EP20000975552 patent/EP1225920A1/en not_active Withdrawn
- 2000-11-02 JP JP2001534425A patent/JP2003528816A/en active Pending
- 2000-11-02 CA CA 2389693 patent/CA2389693A1/en not_active Abandoned
- 2000-11-02 AU AU13591/01A patent/AU785066B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
WO2001032221A1 (en) | 2001-05-10 |
CN1409641A (en) | 2003-04-09 |
JP2003528816A (en) | 2003-09-30 |
NZ538837A (en) | 2007-02-23 |
IL149413A0 (en) | 2002-11-10 |
CA2389693A1 (en) | 2001-05-10 |
AU785066B2 (en) | 2006-09-14 |
EP1225920A1 (en) | 2002-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070042050A1 (en) | Nucleic acid vaccine compositions having a mammalian CD80/CD86 gene promoter driving antigen expression | |
EP1487485B1 (en) | Imidazoquinoline adjuvants for dna vaccines | |
US20030185835A1 (en) | Adjuvant for vaccines | |
US20070237789A1 (en) | DNA-vaccines based on constructs derived from the genomes of human and animal pathogens | |
ZA200503377B (en) | Nucleic acid constructs for gene expression | |
WO2009074861A2 (en) | Improved vaccine | |
EP1379273B1 (en) | Nucleic acid adjuvants | |
AU2001297988A1 (en) | Nucleic acid adjuvants | |
AU785066B2 (en) | DNA-vaccines based on constructs derived from the genomes of human and animal pathogens | |
WO2000063385A2 (en) | Nucleic acid immunization | |
US20060019921A1 (en) | Nucleic acid adjuvants | |
US20040082530A1 (en) | Nucleic acid immunization | |
EP1240343A2 (en) | Nucleic acid vaccine compositions having a mammalian cd80/cd86 gene promoter driving antigen expression | |
US20050148529A1 (en) | Nucleic acid immunization | |
EP1392365A2 (en) | Compositions and therapeutical use of polynucleotides encoding tcrs |